Department Metrics

• Novel Immunotherapy for Brain-Metastatic Breast Cancer
  Award Number:
  Sponsor: US Army
  PI:Czerniecki, B.
• Clinical investigation to improve efficacy of CAR-T Cell Therapy for Large B Cell Lymphoma
  Award Number:
  Sponsor: Leukemia & Lymphoma Society
  PI:Locke, F.
• Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Davila, M.
• High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Overcoming Resistance in HER2 Breast Cancer through a Novel Immunotherapy Approach
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Czerniecki, B.
• Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Identification and assessment of unconventional tumor-associated antigens as potential targets for cytotoxic T-cell based immunotherapy of cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Hwu, P.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Award Number:
  Sponsor: US Army
  PI:Pilon-Thomas, S.
• Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Beg, A.,PI (MPI):Haura, E.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Targeting dendritic cells to improve cancer immunotherapy
  Award Number:
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• Kite Collaboration Master Agreement
  Award Number:
  Sponsor: Kite Pharma
  PI:Locke, F.
• Targeting ER Stress in Pediatric Acute Myeloid Leukemia
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Shaw, T.
• A Clinical Trial of Pirtobrutinib and Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Jain, M.
• IFx-Hu2.0 facilitates immune responses in melanoma
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Markowitz, J.
• Inherited genetic variation as a predictor of the risk of immune related adverse events and the likelihood of clinical benefit
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Tarhini, A.
• CD3z-Independent Signaling Module for CAR-T Cell Therapies Against Solid Cancer
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Guevara, J.
• Bench-bedside-bidirectional investigation of a new combinatorial immunotherapy strategy to treat platinum-resistant penile cancer
  Award Number:
  Sponsor: US Army
  PI:Chahoud, J.
• Dissecting the spatial molecular architecture of the transformed cutaneous T-cell lymphoma tumor microenvironment to target novel therapeutic vulnerabilities
  Award Number:
  Sponsor: US Army
  PI (Contact):Chen, P.
• A Phase 1 Study of CG0070 in Intermediate Risk Non-Muscle Invasive Bladder Cancer
  Award Number:
  Sponsor: BCAN (Bladder Cancer Advocacy Network)
  PI:Li, R.
• γδ T Cell Infusion to Reduce Relapse after HLA Haploidentical Donor Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide
  Award Number:
  Sponsor: Robert A Winn Diversity in Clinical Trials
  PI:Elmariah, H.
• Enhancing Patient Diversity in the PLIGHT Trial: A Multilevel Strategy for Inclusive Enrollment for Asian Population in the Concurrent Phototherapy and POTELIGEO (mogamulizumab-kpkc) Pilot Study for Early-Stage Mycosis Fungoides
  Award Number:
  Sponsor: Robert A Winn Diversity in Clinical Trials
  PI:Zhang, Y.
• Defining Impact of in SITU Activation of CD40 and Type 1 Interferon Signaling on theTME and Systemic T Cell Immunity in Murine models and cancer patients
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Progressive immune dysfunction with advancing disease stage and immune changes post therapy in penile carcinoma
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Chahoud, J.
• Identifying Histopathologic and Molecular Characteristics that Predicts Recurrence in Low Grade Non-Muscle Invasive Bladder Cancer
  Award Number:
  Sponsor: The Hope Fdtn
  PI:Li, R.
• Evaluating B-T cell crosstalk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade
  Award Number:
  Sponsor: US Army
  PI:Karapetyan, L.
• Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers – UG1
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Pidala, J.
• Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Perna, F.
• Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Pilon-Thomas, S.
• Metabolic and Molecular Regulation of Myeloid Cell Functions in Brain Cancer
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Yu, X.
• The role of memory T stem cells in the adoptive transfer of tumor infiltrating lymphocytes
  Award Number:
  Sponsor: Ocala Royal Dames
  PI:Braun, M.
• Research Plan 10: Continued Analysis of Biological Specimens for the Turnstone Process
  Award Number:
  Sponsor: Turnstone Biologics
  PI:Pilon-Thomas, S.
• Regulation of transcriptional programs in mouse and human tumor infiltrating CD8+ T cells
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Zelenka, T.
• Moffitt ACS Post-Baccalaureate Diversity in Cancer Research (MAP-DICR)
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• ENCOURAGE Diversity
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• IMPACT OF TREM2 ON GASTRIC CANCER
  Award Number:
  Sponsor: Amer Gastroenterological Assoc.
  PI:Molgora, M.
• Identifying Risk Factors for Progression and Recurrence in NMIBC Using Artificial Intelligence
  Award Number:
  Sponsor: Valar Labs
  PI:Li, R.
• Investigating Tumor Cell Transcriptomic Heterogeneity Associated with Proximity to Tertiary Lymphoid Structures for Biomarker Discovery in HNSCC
  Award Number:
  Sponsor: Moffitt Cancer Center
  PI:Song, X.
• Soft Materials to Harness the Immune System for Targeted Drug Delivery
  Award Number:
  Sponsor: Moffitt Cancer Center
  PI:Dunne, M.
• Cancer screening behaviors among people with and without HIV in All of Us
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,Project PI:Islam, J.

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 20888
Predicting the Quality of Response to Specific Treatments (PQRST) Chronic GVHD Cohort
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21192
A Phase 2 Study of the Combination Dostarlimab with Niraparib In Patients with Penile Carcinoma Who Have Progressed Following Chemotherapy
Condition: Genitourinary
Intervention: Dostarlimab (); Niraparib (); TSR-042 (Dostarlimab)

CLINICAL TRIAL 21213
A Single-Arm, Open-Label Phase 1b Study of Hyper-CVAD + Calaspargase pegol in Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: Calaspargase pegol ()

CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21341
A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Ziv-aflibercept ()

CLINICAL TRIAL 21351
A Prospective Analysis of Biochemical Markers for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy in Adults
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 21676
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases (TARGET-TNBC)
Condition: Breast
Intervention: Sacituzumab Govitecan (); Zimberelimab ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 21763
MRKR-21-401-OTS - A Phase 1 Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cells (MT-401-OTS) Administered to Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
Condition: Malignant Hematology
Intervention: Azacitidine (5-azacitidine); Bendamustine (); MESNA (); MT-401-OTS (); cyclophosphamide (); cytoxan (cyclophosphamide); decitabine (5-aza-2'-deoxycytidine); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23460
A Multicenter Phase I/Ib Dose Escalation Study of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)

CLINICAL TRIAL 21955
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma after Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Tafasitamab ()

CLINICAL TRIAL 22079
A Phase 1/2, Open-Label Study of PD-1 Knockout Tumor-Infiltrating Lymphocytes (IOC-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-Small-Cell Lung Cancer
Condition: Cutaneous
Intervention: IL-2 (Interleukin-2); IOV-4001 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22080
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: Adriamycin (doxorubicin); Axicabtagene Ciloleucel (Yescarta); Etoposide (); Rituxan (rituximab); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); fludarabine (Fludarabine phosphate); prednisone (); rituximab ()

CLINICAL TRIAL 22114
Randomized Phase II study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft vs. Host Disease
Condition: Malignant Hematology
Intervention: Belumosudil (); KD025 (Belumosudil); Placebo ()

CLINICAL TRIAL 22286
Phase 2 Study of KTE-X19 in MRD Positive B-ALL
Condition: Malignant Hematology
Intervention: KTE-X19 (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 22349
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
Condition: Genitourinary
Intervention: JNJ-42756493 (Erdafitinib)

CLINICAL TRIAL 22505
Cutaneous Adverse Events (irCAEs) Associated with Immunotherapy in Patients with Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 22536
Immune Profiling of Relatlimab and Nivolumab Combination Immunotherapy for Advanced Stage Metastatic Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 22554
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Condition: Cutaneous
Intervention: Albumin-Bound Paclitaxel (); BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); DTIC (Dacarbazine); Dacarbazine (); IL-2 (Interleukin-2); IMA203 (); Ipilimumab (); Lifileucel (); Nivolumab (Opdivo); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Relatlimab (); Taxol (paclitaxel); Temodal (Temozolomide); Temozolomide (); Yervoy (Ipilimumab); carboplatin (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); paclitaxel ()

CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 22695
ADI-PEG 20 (Pegargiminase) or Placebo (PBO) plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Condition: Sarcoma
Intervention: ADI-PEG 20 (); Gemzar (gemcitabine); Placebo (); Taxotere (docetaxel); docetaxel (); gemcitabine ()

CLINICAL TRIAL 23082
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients with Advanced Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); Proleukin (Interleukin-2); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23135
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Condition: Malignant Hematology
Intervention: BMS-986393 (); Tocilizumab (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23184
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)
Condition: Malignant Hematology
Intervention: Placebo ()

CLINICAL TRIAL 23142
Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer after Neoadjuvant Therapy
Condition: Breast
Intervention: DC1 Vaccine ()

CLINICAL TRIAL 23228
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
Condition: Sarcoma
Intervention: DCC-2618 (Ripretinib); Ripretinib (); Sunitinib ()

CLINICAL TRIAL 23229
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Condition: Multiple
Intervention: Lenti-HPV-07 ()

CLINICAL TRIAL 23275
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23240
A Phase 1, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy Of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway And With Other Solid Tumors
Condition: Cutaneous
Intervention: NST-628 ()

CLINICAL TRIAL 23298
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment Of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: Pembrolizumab (Keytruda); Placebo (); Zanzalintinib ()

CLINICAL TRIAL 23300
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Condition: Genitourinary
Intervention: Erdafitinib (); Gemzar (gemcitabine); JNJ-42756493 (Erdafitinib); gemcitabine (); mitomycin c ()

CLINICAL TRIAL 23652
A Phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory (R/R) CD19+ hematologic malignancies
Condition: Malignant Hematology
Intervention: Rapamycin (Sirolimus); UB-VV111 ()

CLINICAL TRIAL 23320
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients with CD5 Positive (CD5+) Relapsed/Refractory T-cell Lymphoma (r/r TCL)
Condition: Malignant Hematology
Intervention: MB-105 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23321
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Anitocabtagene autoleucel (); Bortezomib (); CC-4047 (Pomalidomide); Daratumumab (Darzalex); Dexamethasone (); PS-341 (Bortezomib); Pomalidomide (); Velcade (Bortezomib); carfilzomib (Kyprolis); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23340
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Condition: Breast
Intervention: Alisertib (MLN8237); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Letrozole (); Tamoxifen (); fulvestrant ()

CLINICAL TRIAL 23363
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)
Condition: Malignant Hematology
Intervention: ALLO-647 (); Cema-cel (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23421
A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Placebo (); Vitamin A ()

CLINICAL TRIAL 23433
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer following Neoadjuvant Chemotherapy and Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23455
A phase I/IB study of Ropeginterferon in patients with Cutaneous T-Cell Lymphoma (CTCL)
Condition: Malignant Hematology
Intervention: Ropeginterferon alfa-2b (P1101) ()

CLINICAL TRIAL 23453
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Condition: Malignant Hematology
Intervention: AZD0486 ()

CLINICAL TRIAL 23473
A Phase II Study Assessing the Feasibility and Clinical Efficacy of Adaptive Immunotherapy Combination with VEGFR-TKI in Patients with Advanced Renal Cell Carcinoma
Condition: Genitourinary
Intervention: Pembrolizumab (Keytruda); axitinib (AG-013736)

CLINICAL TRIAL 23475
A Phase 1/2 Study of OR502 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
Condition: Cutaneous
Intervention: Cemiplimab (); OR502 (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 23598
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Condition: Genitourinary
Intervention: Sacituzumab tirumotecan ()

CLINICAL TRIAL 23641
A Phase 2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Condition: Malignant Hematology
Intervention: Vimseltinib ()

CLINICAL TRIAL 23572
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Condition: Breast
Intervention: Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

CLINICAL TRIAL 23624
A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
Condition: Malignant Hematology
Intervention: Sonrotoclax (); Zanubrutinib ()

CLINICAL TRIAL 23706
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta)

CLINICAL TRIAL 23711
Artificial Intelligence-Integrated Clinical, Pathologic, Genomic, and Radiologic Model for Predicting Response to Complex Immunotherapies and Risk of Developing Extramedullary Disease in Multiple Myeloma
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()

CLINICAL TRIAL 23939
Distinguishing Breast and Cutaneous Tumors
Condition: Breast
Intervention:

• Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025 Dec.14(1):2546402. Pubmedid: 40815607. Pmcid: PMC12360205.
• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• von Deimling M, Furrer M, Bianchi A, Pichler R, Maas M, Tully KH, Longoni M, Mertens LS, Taylor J, Del Giudice F, Li R, Gallioli A, Albisinni S, Crocetto F, Velev M, Afferi L, Mari A, Laukhtina E, Klemm J, Singla N, Fisch M, Spiess PE, Lotan Y, Moschini M, Black PC, Antonelli A, Kiss B, Shariat SF, Pradere B. Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. BJU Int. 2025 Nov.136(5):911-919. Pubmedid: 40631580. Pmcid: PMC12522521.
• Lee MS, Hensley PJ, Igel D, Li R, Clark RK, Bingham N, Pallauf M, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Oncologic and survival outcomes in patients undergoing radical nephroureterectomy with preoperative or iatrogenic dialysis dependence. Urol Oncol. 2025 Nov.43(11):662.e9-662.e15. Pubmedid: 40754548.
• Cruz-Chamorro R, Bryant JM, Henning J, Robinson LA, Lee DH, Fontaine J, Toloza E, Rosenberg SA, Kim J, Naqa IE, Dilling TJ. Factors impacting cardiac dose and overall survival in post-operative non-small cell lung cancer patients. Radiother Oncol. 2025 Nov.212:111117. Pubmedid: 40854381.
• Deek RA, Kim J, Kumar R, Medina B, Langenfeld J, Kontopidis I, Lazzaro R, Nie K, Hathout L, Guler O, Onal C, Patel E, Haigentz M, Jabbour SK, Deek MP. Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer. Clin Lung Cancer. 2025 Nov.26(7):e609-e615.e11. Pubmedid: 40897601.
• Weinfurtner RJ, Ataya D, Funaro K, Bhatt A, Abdalah M, Stringfield O, Raghunand N, Thompson Z, Lee MC, Czerniecki B, Muller AS, Soliman H, Han H. Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy. Clin Imaging. 2025 Nov.127:110618. Pubmedid: 40945432.
• Lee SJ, Logan B, Horowitz MM, Dehn JG, Pidala J, Grunwald MR, Westervelt P, Farhadfar N, Hogan WJ, Bashey A, Hayes-Lattin B, Hill L, Brunstein C, Arai S, Srour SA, Symons H, Uberti J, Vasu S, Pusic I, Juckett M, Leifer E, He N, Devine S, Shaw BE, Ciurea SO. Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. J Clin Oncol. 2025 Nov.43(31):3369-3380. Pubmedid: 40966481.
• Rollison DE, Garcia MA, Amorrortu RP, Zhao Y, Mittman B, Turner K, Kirtane K, Soliman H, Byrne MM, Meade C, Gwede CK, Eschrich S, Yin J, Stanley NB, Fuzzell L, Hernandez D, Tapia-Kwan E, Vadaparampil ST. Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER2S study. Contemp Clin Trials. 2025 Nov.158:108096. Pubmedid: 40992541.
• Jazayeri B, Wang X, Li R. Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. Eur Urol. 2025 Oct. Pubmedid: 41107180.
• Gaskill E, Albanyan O, Naqvi SMH, Mo Q, Belfon A, Nishihori T, Faramand R, Lazaryan A, Hansen DK, Khimani F, Mishra A, Nieder M, Perez L, Liu H, Pidala J, Anasetti C, Bejanyan N, Elmariah H. Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Transplant Cell Ther. 2025 Oct. Pubmedid: 41115629.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2025 Oct. Pubmedid: 41117857.
• Hatoum F, Souza GR, Johnson J, Miller J, Fazili A, Pettaway CA, Campbell MT, Neubauer R, Johns A, Mizelle SR, Kim Y, Chadha J, Zhang J, Jameel G, Oschmann E, Dhillon J, Moscu A, Janeway R, Harris W, Lu X, Spiess PE, Chahoud J. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma. Future Oncol. 2025 Oct.1-9. Pubmedid: 41163621.
• Dugan MM, Balsay-Patel C, Chin N, Israeli J, Ward KR, Nichols M, Greenbaum S, Fan W, Cruse CW, Harrington M, Neves RI, Gonzalez RJ, Perez MC, Sarnaik AA, Sondak VK, Messina JL, Tarhini AA, Khushalani N, Brohl AS, Markowitz J, Eroglu Z, Karapetyan L, Tsai KY, Zager JS. Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy. Ann Surg Oncol. 2025 Oct. Pubmedid: 41168606.
• Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Clin Trials. 2025 Oct.22(5):571-577. Pubmedid: 40099861. Pmcid: PMC12353050.
• Chang SS, Launer B, Narayan V, Patil D, O'Donnell MA, Hensley PJ, Taylor JA, Li R, Fernandez MI, Zhang H, Krishna V, Vrabac D, Abuzeid WM, Nimgaonkar V, Watson D, Royce TJ, Kiedrowski LA, Joshi A, Konety BR, Spiess PE, Williams SB, Packiam VT, Kamat AM, Lotan Y, Daneshmand S. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stra. Eur Urol. 2025 Oct.88(4):411-413. Pubmedid: 40514253.
• Katims AB, Tin AL, Assel M, Hensley P, Li R, Margulis V, Matin S, Pallauf M, Clark RK, Raman JD, Singla N, Spiess PE, Coleman J. Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration). J Urol. 2025 Oct.214(4):407-414. Pubmedid: 40526449. Pmcid: PMC12355653.
• Schmitz J, Gaskill E, Price S, Cao B, Kim J, Baluch A, Klinkova O, Faramand R, Mishra A, Perez L, Khimani F, Lazaryan A, Ochoa-Bayona JL, Liu H, Mirza AS, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. Bone Marrow Transplant. 2025 Oct.60(10):1383-1386. Pubmedid: 40617898.
• Kluger H, Grigoleit GU, Thomas S, Domingo-Musibay E, Chesney JA, Sanmamed MF, Medina T, Ziemer M, Whitman E, Finckenstein FG, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik AA. Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Commun (Lond). 2025 Oct.45(10):1229-1234. Pubmedid: 40693376. Pmcid: PMC12531414.
• Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Oct.32(11):8211-8219. Pubmedid: 40699532. Pmcid: PMC12494629.
• Ahmed N, Thiruvengadam S, Hamadani M, Hu ZH, Grover NS, Shadman M, Locke FL, Gerson J, Frank MJ, Budde LE, Wang ML, Kim S, Bye M, Kharfan-Dabaja MA, Sauter CS, Hematti P, Turtle CJ, Ahmed S, Moskop A, Logan BR, Nunes A, Dalton DM, Kloos IM, Lee D, Xu H, Pasquini MC, Herrera AF. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025 Oct.9(20):5382-5396. Pubmedid: 40706035.
• Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Oct.32(11):8243-8253. Pubmedid: 40705266. Pmcid: PMC12494636.
• Uriepero-Palma A, Marquez ME, Payque E, Mediavilla-Varela M, Gamal W, Maharaj K, Powers JJ, Eksioglu EA, Chavez JC, Sernbo S, Palacios F, Querol Rivas J, Ortega C, Uria R, Dos Santos G, Oliver C, Landoni AI, Sahakian E, Oppezzo P, Pinilla-Ibarz J. Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL. Blood Adv. 2025 Oct.9(20):5219-5233. Pubmedid: 40720748. Pmcid: PMC12550715.
• Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct.146(17):2063-2072. Pubmedid: 40749169.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Dineen S, O'Leary C, Rajasekhara S, Mullinax J. Implementation of a Palliative Surgical Oncology Rotation to Complex General Surgical Oncology Fellowship Training. Ann Surg Oncol. 2025 Oct.32(10):7124-7130. Pubmedid: 40849382.
• Shah BD, Xue M, Furnback W, Yang K. Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. Future Oncol. 2025 Oct.21(23):3043-3049. Pubmedid: 40916371. Pmcid: PMC12490371.
• Hudson K, Gathirua-Mwangi W, Williams LA, Cui ZL, Richey M, Grimes B, Wang J, Liepa AM, Brechtelsbauer E, Volodarsky R, Moreira K, Soliman H. Abemaciclib Persistence in Patients with HR+, HER2-, Node-Positive Early Breast Cancer: a Real-World Analysis. Oncol Ther. 2025 Oct. Pubmedid: 41039165.
• Guerrieri RA, Fischer GM, Cortez JR, Knighton BG, Ledesma DA, Hudgens CW, Delcid YF, Hu Q, Onana CYB, Carapeto FCL, Tezlaff MT, Huse JT, Hwu P, Burton EM, Glitza Oliva IC, Davies MA, Ferguson SD. Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Sci Rep. 2025 Oct.15(1):34352. Pubmedid: 41038921. Pmcid: PMC12491558.
• Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder. Eur Urol. 2025 Oct. Pubmedid: 41046180.
• Oseni SO, Wang Y, Hwu P. Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. Trends Cancer. 2025 Oct.11(10):934-965. Pubmedid: 41046167.
• Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Dabaja MK, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Ne. 2025 Oct.23(10). Pubmedid: 41067275.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Oct. Pubmedid: 41072416.
• Li R, Hensley PJ, Babjuk M, Bukavina L, Psutka SP, Lerner SP, O'Donnell MA, Lotan Y, Bree KK, Redorta JP, McConkey DJ, Lee BH, Mariappan P, Mertens LS, Soloway MS, Svatek RS, Tan WS, Williams SB, Gupta S, Buckley R, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Oct. Pubmedid: 41076366.
• Jain MD, Cools-Lartigue J. Immune dysfunction after cancer remission: scar or disease?. Blood. 2025 Sep.146(11):1255-1257. Pubmedid: 40932742.
• Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2025 Sep. Pubmedid: 40932312.
• Huynh THN, Clampitt BA, Chose CM, Nester MD, Joyce DM, Binitie OT, Freeman CL, Lazarides AL. Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma. J Am Acad Orthop Surg. 2025 Sep. Pubmedid: 40953403.
• Potez M, Jazayeri SB, Guske C, Miller J, Ali J, Carter M, Khambati F, Dhillon J, Sexton W, Zemp L, Manley B, Souza GR, Spiess PE, Beatty M, Pilon-Thomas S, Chahoud J. Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma. Eur Urol. 2025 Sep. Pubmedid: 40962596.
• Feng BJ, Kohlmann W, Nix DA, Atkinson A, Boucher KM, Carroll C, Stubben CJ, Kolesar J, Singer EA, Riedlinger G, Edge S, Sahu KK, Churchman M, Graham L, Salhia B, Sanchez A, Zakharia Y, Schneider BP, Jain R, Byrne L, Moskaluk CA, Nepple K, Shabsigh A, Chahoud J, Cairns BR, Gupta S. Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape. J Immunother Cancer. 2025 Sep.13(9). Pubmedid: 40962358. Pmcid: PMC12443205.
• Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplant Cell Ther. 2025 Sep. Pubmedid: 40972962.
• Zhang Y, Qin D, Ozoya O, Glass F, Sokol L, Ryder CB. Expanded CD4+CD57+ T-large granular lymphocytes: A diagnostic pitfall in blood staging of mycosis fungoides/Sézary syndrome. Am J Clin Pathol. 2025 Sep. Pubmedid: 40972673.
• Parker NH, Ramos JD, Tarhini AA, Schell MJ, Egan KM, Kanetsky PA. A retrospective cohort study of physical activity and survival in patients treated with immune checkpoint inhibitors. Cancer Epidemiol Biomarkers Prev. 2025 Sep. Pubmedid: 40971247. Pmcid: PMC12579459.
• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2025 Sep. Pubmedid: 40983035.
• Perez DH, Antfolk D, Chang S, Bustos XE, Medina E, Ramadan AA, Gonzalez-Perez D, Abate-Daga D, Rodriguez PC, Luca VC. Engineering synthetic agonists for targeted activation of Notch signaling. Nat Chem Biol. 2025 Sep. Pubmedid: 40993428.
• Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med. 2025 Sep. Pubmedid: 40993242.
• Ardila V, Onstad L, Carpenter P, Pidala J, Kitko C, Jurdi NE, Lee SJ, Hamilton BK. Obesity Associations with Chronic Graft-Versus-Host Disease. Transplant Cell Ther. 2025 Sep. Pubmedid: 40998267.
• Titus RS, Mundra V, Velasquez EL, Xu J, Riveros C, Ranganathan S, Porika A, Reddy R, Kaushik D, Kukreja J, Li R, Wallis CJD, Satkunasivam R. The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database. Urol Oncol. 2025 Sep. Pubmedid: 41006132.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells. 2025 Sep.14(18). Pubmedid: 41002423. Pmcid: PMC12468907.
• Jaime-Casas S, Barragan-Carrillo R, Eskenazi F, Dugarte JP, Chahoud J, Spiess PE, Medina LG. Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer. Cancers (Basel). 2025 Sep.17(18). Pubmedid: 41008800. Pmcid: PMC12468617.
• Potez M, Roman Souza G, Spiess PE, Pilon-Thomas S, Chahoud J. The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. Nat Rev Urol. 2025 Sep. Pubmedid: 41006825.
• Louloudis IE, Chen YB, Spyrou N, Alousi A, Katsivelos N, Ayuk F, Weber D, Hogan WJ, Etra AM, Qayed M, Aguayo-Hiraldo P, Akahoshi Y, Malki MMA, Bolaños-Meade J, Chanswangphuwana C, Diniz M, Eder M, Hexner E, Kitko CL, Kraus S, Merli P, Olson T, MacMillan ML, Pidala J, Reshef R, Schechter T, Wölfl M, Baez J, Eng G, Gleich S, Young R, Nakamura R, Ferrara JLM, Levine JE. Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity. Transplant Cell Ther. 2025 Sep. Pubmedid: 41015085.
• Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, Kanakry CG, Lazaryan A. Role of Donor Cytomegalovirus Serostatus in Cytomegalovirus-Seronegative Recipients of Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis. Transplant Cell Ther. 2025 Sep.31(9):672.e1-672.e9. Pubmedid: 40379049.
• Diamond B, Chahar D, Jain MD, Poos AM, Durante MA, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan KH, Jelinek T, Davies FE, Figura NB, Morgan GJ, Mai EK, Weisel K, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies. Blood Cancer Discov. 2025 Sep.6(5):450-463. Pubmedid: 40402512. Pmcid: PMC12405863.
• Lee SJ, Williams KM, Sarantopoulos S, Kitko CL, Cutler C, Pidala J, Hill GR, DeFilipp Z, Greinix HT, Wolff D, Paczesny S, Cuvelier GDE, Schultz KR, Pavletic SZ. NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 Update. Transplant Cell Ther. 2025 Sep.31(9):678.e1-678.e16. Pubmedid: 40409691. Pmcid: PMC12354025.
• Ghobadi A, Aldoss I, Maude SL, Bhojwani D, Wayne AS, Bajel A, Dholaria B, Faramand RG, Mattison RJ, Rijneveld AW, Zwaan CM, Calkoen FG, Baruchel A, Boissel N, Rettig MP, Wood B, Jacobs K, Christ S, Irons H, Capoccia B, Masters D, Gonzalez J, Wu T, Del Rosario M, Hamil A, Bakkacha O, Muth J, Ramsey B, McNulty E, Baughman J, Cooper ML, Davidson-Moncada JK, DiPersio JF. Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies. Blood. 2025 Sep.146(10):1163-1173. Pubmedid: 40445850.
• Elmariah H, Kim J, Gonzalez R, DiMaggio E, Sansil S, Mishra A, Faramand R, Perez L, Lazaryan A, Mirza AS, Khimani F, Liu H, Ochoa-Bayona JL, Nieder M, Perna F, Figura N, Robinson TJ, Nishihori T, Anasetti C, Pidala JA, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant. Am J Hematol. 2025 Sep.100(9):1665-1669. Pubmedid: 40492500.
• Hwang SM, Chang S, Rodriguez PC, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in anticancer immunity. Nat Rev Cancer. 2025 Sep.25(9):684-702. Pubmedid: 40555746. Pmcid: PMC12486299.
• Davis EW, Park MA, Basinski TL, Arnoletti JP, Bloomston M, Carson TL, Biachi De Castria T, Chen DT, Cortizas EM, Crowder SL, Genilo-Delgado M, Douglas WG, Huguet KL, Jiang K, Hodul PJ, Karolak A, Kim DW, Koomen JM, Menon AA, Mo Q, Mok SR, Molina-Vega MA, Moreno-Urazan L, Ahmed S, Parker NH, Pimiento JM, Rasool G, Sparks LM, Stewart PA, Tassielli AF, Teer JK, Trevino JG, Velanovich V, Wang X, Whelan CJ, Judge SM, Judge AR, Fleming JB, Malafa MP, Jeong D, Permuth JB. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2025 Sep.34(9):1609-1617. Pubmedid: 40553455.
• Locke FL, Le Gall JB, Fisher PW, Neelapu SS. Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching. J Clin Oncol. 2025 Sep.43(25):2834-2835. Pubmedid: 40549998.
• Giridharan T, Suzuki S, Khan ANH, Liu Q, Attwood K, Stokolosa A, Mahan S, Witkiewicz AK, Joseph J, Moysich K, Langermann S, Lovewell R, Flies D, Myint H, Odunsi K, Emmons TR, Yaffe MB, Zsiros E, Dey P, McGray AJR, Segal BH. NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression. J Immunol. 2025 Sep.214(9):2464-2479. Pubmedid: 40560129. Pmcid: PMC12481037.
• Hijazi A, Locke FL, Scholler N, Mattie M, Filosto S, Bedognetti D, Galon J. Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma. Clin Cancer Res. 2025 Sep.31(18):3834-3843. Pubmedid: 40622821. Pmcid: PMC12434396.
• Cobb JK, Miyagi H, Chahoud J, Bassil C, Spiess PE. Management and optimization of chronic renal insufficiency in the setting of kidney cancer A Systematic Review. Int Braz J Urol. 2025 Sep.51(5). Pubmedid: 40658472. Pmcid: PMC12539876.
• Shah B, Challagulla S, Xu S, Williams R, Ren S, Srivastava T, Gautam R, Yang K, Saba NS, Tam CS. Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma. Leuk Lymphoma. 2025 Sep.1-11. Pubmedid: 40889741.
• Dineen S, Mullinax J. ASO Author Reflections: Emphasizing Surgical Palliative Care in CGSO Fellowship Programs. Ann Surg Oncol. 2025 Sep. Pubmedid: 40924245.
• Wen L, Miyagi H, Spiess PE, Yu A, Mendelsohn CL, Tan WS, Psutka SP, Lerner SP, Cheng L, Dyrskjøt L, Meeks JJ, Shariat SF, Gontero P, Pradere B, Steinberg GD, Kamat AM, Li R. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nat Rev Urol. 2025 Sep. Pubmedid: 40931081.
• Perales MA, Oluwole OO, Patel AR, Ray MD, Rodriguez-Guadarrama YA, Smith NJ, Blissett R, Yang Y, Locke FL. Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma. Transplant Cell Ther. 2025 Sep. Pubmedid: 40930226.
• Hatoum F, Fazili A, Miller JW, Wang X, Yu X, Lu X, S Johnson J, Spiess PE, Chahoud J. Current Role and Future Frontiers of Spatial Transcriptomics in Genitourinary Cancers. Cancers (Basel). 2025 Aug.17(17). Pubmedid: 40940870. Pmcid: PMC12427188.
• Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, Li R, Roy-Chowdhuri S, Montironi R, Golijanin D, Luchini C, Cheng L. Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. Eur Urol Focus. 2025 Aug. Pubmedid: 40753029.
• Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Aug. Pubmedid: 40754223.
• Basta A, Lien K, Sun W, Whiting J, Armitage M, Soyano AE, Armaghani A, Loftus L, O Apos Connor T, Dvir K, Han HS, Soliman H, Czerniecki BJ, Costa RLB. A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer. Oncology-Basel. 2025 Aug.1-10. Pubmedid: 40759100.
• Yao S, Li T, Davis JT, Shaw TI, Yu X, Wang X. SmartImpute is a targeted imputation framework for single-cell transcriptome data. Cell Rep Methods. 2025 Aug.5(8):101122. Pubmedid: 40763742. Pmcid: PMC12461658.
• Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Dhrubo D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodriguez-Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real world survival estimation. Res Sq. 2025 Aug. Pubmedid: 40799741. Pmcid: PMC12340904.
• Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Oloyede T, Awan FT, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen AF, Dholaria B, Farooq U, Foglesong J, Ganguly S, Hematti P, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, McGuirk JP, Mead E, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Ramakrishnan Geethakumari P, Riedell PA, Saber W, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse CS, Turtle CJ, Valluripalli A, Wudhikarn K, Pasquini MC, Ahmed S, Sorror ML. New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma. Blood Adv. 2025 Aug. Pubmedid: 40811818.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Nikhil IK, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Aug. Pubmedid: 40813711. Pmcid: PMC12419231.
• Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld AK, Anderson C, Lin C, Moreno Vanegas YA, Badar T, Coltoff A, Knepper TC, Ozkaya N, Youshanlouei HR, Cetin S, Patel AA, DuVall AS, Drazer MW, Wang P, Tjota M, Segal JP, Venkataraman G, Gurbuxani S, Cheng JX, Arber DA, Larson RA, Odenike O, Webster J, Shah B, Stock W, Saygin C. Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug.15(1):138. Pubmedid: 40813576. Pmcid: PMC12354737.
• Phadke MS, Li J, Sriramareddy S, Rodriguez PC, Ruffell B, Luca VC, Tran TTT, Chen YA, Smalley KSM. Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. J Immunother Cancer. 2025 Aug.13(8). Pubmedid: 40825611. Pmcid: PMC12366563.
• Yepez V, Yang MJ, Washington S, Jones S, Poudel R, Pidala J, Horta M, Vinci C. AutoFOCUS: A mindfulness-based intervention for caregivers of autologous hematopoietic stem cell transplant recipients. Palliat Support Care. 2025 Aug.23:e147. Pubmedid: 40842352. Pmcid: PMC12491394.
• Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, van 't Veer L, Boughey JC. ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 Aug. Pubmedid: 40849378.
• O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 Aug. Pubmedid: 40849364.
• Lehner K, Li R, Hensley PJ, Clark RK, Pallauf M, Katims A, Bingham N, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Smoking is Associated With Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer. Urology. 2025 Aug. Pubmedid: 40848880.
• Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE, Wada DA, Plaza JA, Sosman JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS, Khushalani NI, Markowitz J, Negrea G, Kasbari S, Doolittle GC, Swami U, Roberts T, Mathew BN, Medina E, Baselga-Carretero I, Gonzalez CR, Garcilazo IP, Vega-Crespo A, Chen JM, Naser Al-Deen N, Patel SP, Sharon E, Moon J, Wu MC, Ribas A. Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025 Aug. Pubmedid: 40858972.
• Winkelmann M, Raj SS, Jain MD, Iacoboni G, Müller F, Hansmann L, Corona M, Luna A, Jhaveri K, Shah GL, Scordo M, Mohammad T, Dean EA, Sheikh GT, Kunz WG, Tix T, Bücklein VL, Bedmutha A, Leithner D, von Bergwelt-Baildon M, Boardman AP, Palomba ML, Park JH, Salles G, Perales MA, Schöder H, Subklewe M, Barba P, Locke FL, Shouval R, Rejeski K. Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. Blood Cancer J. 2025 Aug.15(1):144. Pubmedid: 40858552. Pmcid: PMC12381142.
• Sweet K, Pinilla-Ibarz J. Asciminib in late-line CML treatment. Blood Adv. 2025 Aug.9(16):4317-4318. Pubmedid: 40827887. Pmcid: PMC12395050.
• Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE, Teng MN, Pilon-Thomas S, Binning JM. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Mol Ther. 2025 Aug. Pubmedid: 40873032.
• Hall K, Lazaryan A, Der Laan MV, Lee CJ, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota LM, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the US. Blood Adv. 2025 Aug. Pubmedid: 40875591.
• Piña Y, Law V, Sahebjam S, Tran N, Siddarajappa N, Li J, Mo Q, Phadke MS, Arrington J, Macaulay R, Mokhtari S, Evernden B, Ahmed KA, Smalley I, Yu M, Smalley KSM, Forsyth PA. Phase IB Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD) from Solid Tumors: Results and Molecular Analyses. Neurooncol. 2025 Aug. Pubmedid: 40888040.
• Morrison SL, Han G, Elenwa F, Leong SP, Kashani-Sabet M, Pockaj B, Kosiorek HE, White RL, Zager JS, Messina JL, Sondak V, O'Donoghue C, Howard JH, Schneebaum S, Olofsson Bagge R, Namm JP, Garberoglio C, Avisar E, Fowler G, Han D, Vetto J. Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis. Am J Surg. 2025 Aug.246:116243. Pubmedid: 39979140.
• Davids MS, Kenderian SS, Flinn IW, Hill BT, Maris MB, Ghia P, Byrne MT, Bartlett NL, Pagel J, Zheng Y, Kanska J, Zhang W, Granados E, Pinilla-Ibarz J. ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2025 Aug.146(8):938-943. Pubmedid: 40209059.
• Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: 40253586. Pmcid: PMC12461620.
• Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini MC, Raj SS, Rajeeve S, Salles GA, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid OB, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025 Aug.146(7):834-846. Pubmedid: 40258181.
• Singh S, Julia E, Kalita P, Mason C, Ming Q, Lee-Sam A, Gordon S, Buitrago ME, Leung DW, Hwu P, Luca VC. Structure-guided engineering of CD112 receptor variants for optimized immunotherapy. Mol Ther. 2025 Aug.33(8):3590-3604. Pubmedid: 40285356. Pmcid: PMC12368799.
• Jain RK, Swami U, Bilen MA, Gebrael G, Boucher KM, Braun E, Brown JT, Chahoud J, Gupta S, Agarwal N, Sonpavde G, Maughan BL. Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. Eur Urol Oncol. 2025 Aug.8(4):952-960. Pubmedid: 40307092.
• Fazili A, Sirard RB, Thompson Z, Wen L, Jazayeri SB, Naso C, Freamon C, Tighe J, Chahoud J, Spiess PE. Early postoperative visits improve outcomes in inguinal lymph node dissection for penile cancer. BJU Int. 2025 Aug.136(2):289-296. Pubmedid: 40318206.
• Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug.9(16):4081-4089. Pubmedid: 40334068. Pmcid: PMC12359224.
• Tarhini AA, Obermayer A, Lee SJ, LaFramboise WA, Hodi FS, Karunamurthy AD, Eljilany I, Chen DT, Hwu P, El Naqa IM, Streicher H, Sondak VK, Storkus WJ, Butterfield LH, Shaw TI, Kirkwood JM. Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clin Cancer Res. 2025 Aug.31(15):3249-3258. Pubmedid: 40392969. Pmcid: PMC12316551.
• Lee KT, Hu B, Martinez Tyson D, Geiss C, Vadaparampil ST, Jim HSL, Gwede CK, Soliman HH, Henry NL, Hershman DL. A mixed-methods study characterizing experiences of medical oncologists' use of gonadotropin-releasing hormone agonists for treatment of breast cancer. Breast Cancer Res Treat. 2025 Aug.212(3):449-455. Pubmedid: 40461861. Pmcid: PMC12209034.
• Kharfan-Dabaja MA, Kumar A, Pinilla-Ibarz J, Brown JR, Shadman M, Awan FT, Kenderian SS, Siddiqi T, Abramson JS, Al-Juhaishi T, Brander DM, Coombs CC, Furman RR, Jain N, Khan N, Saba NS, Collins JM, Beitinjaneh A, Stephens DM, Woyach J, Hamadani M. Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Th. Transplant Cell Ther. 2025 Aug.31(8):494-504. Pubmedid: 40514010.
• Rishi A, Albuquerque KV, Jhingran A, Donovan EK, Horne ZD, Ludwig MS, Pathak P, Goldsberry R, Glaser SM, Garg A, Yin V, Fernandez DC, Beriwal S, Ahmed KA, Montejo ME. Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study. Gynecol Oncol. 2025 Aug.199:1-9. Pubmedid: 40513383.
• Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
• Pichler R, Subiela JD, Mayr R, Moschini M, Li R, Pradére B. Local Therapy of the Primary Tumor: An Option for Metastatic Urothelial Carcinoma in the Era of Novel Combination Therapies?. Eur Urol Open Sci. 2025 Aug.78:69-71. Pubmedid: 40698267. Pmcid: PMC12281547.
• Ahmed KA, Kim Y, Armaghani AJ, Arrington JA, Costa RL, Czerniecki BJ, Diaz R, Dowell RA, Extermann M, Forsyth PA, Lee KT, Loftus L, Mills MN, Phuoc VH, Rosa M, Soliman HH, Sam CS, Washington IR, Soyano AE, Han HS. Phase II trial of brain MRI surveillance in stage IV breast cancer. Neurooncol. 2025 Jul.27(6):1550-1558. Pubmedid: 39851040. Pmcid: PMC12309701.
• Joshi U, Budhathoki P, Gaire S, Yadav SK, Niu C, Agrawal V, Low SK, Soliman HH. Clinical Outcomes and Prognostic Factors in Epithelial-Myoepithelial Carcinoma (EMC) of the Breast. Clin Breast Cancer. 2025 Jul.25(5):e511-e516.e8. Pubmedid: 39934001.
• Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis LJ, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF. Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. Blood. 2025 Jul.146(4):422-436. Pubmedid: 40090005.
• Morse B, Jeong D, Ahmed A, Kim J, Spiess P, Chahoud J. Preoperative prediction of high-risk lymph nodes in penile cancer: Graafland criteria vs radiomics. BJU Int. 2025 Jul.136(1):45-46. Pubmedid: 40130666.
• Wen L, Li R. Editorial Comment. J Urol. 2025 Jul.214(1):31. Pubmedid: 40197089.
• Yegya-Raman N, Plastaras JP, Wright CM, Chelius MR, Zhang S, Baron JA, Hubbeling H, Sim AJ, Robinson TJ, Jain MD, Imber BS, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix CC, Gunther JR, Fang PQ, Wu SY, Dabaja BS, Yang JC, Chew J, Braunstein S, Sinha S, Denlinger N, Sun S, Terezakis SA, Sakthivel G, Constine LS, Chowdhry AK, Reagan PM, Burke S, Tseng YD, LaRiviere MJ, Maity A, Schuster SJ, Chong EA, Figura NB. Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study. Blood Adv. 2025 Jul.9(13):3293-3303. Pubmedid: 40203192. Pmcid: PMC12268022.
• Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: 40198886.
• Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv. 2025 Jul.9(14):3429-3440. Pubmedid: 40198765. Pmcid: PMC12274813.
• Lotan Y, Li R, Chang SS. Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin-Treated Nonmuscle-Invasive Bladder Cancer. J Urol. 2025 Jul.214(1):90-91. Pubmedid: 40239974.
• Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD. Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2025 Jul.31(13):2756-2766. Pubmedid: 40238583. Pmcid: PMC12213223.
• Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA. A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer. Eur Urol. 2025 Jul.88(1):33-55. Pubmedid: 40253283.
• Shah B, Xue M, Furnback W, Seymour EK, Kim J, Chuang PY, Dec M, Yang K. A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma. Pharmacoecon Open. 2025 Jul.9(4):541-570. Pubmedid: 40263163. Pmcid: PMC12209080.
• Dugan MM, Beekman KE, DePalo DK, Parker LM, Elleson KM, Mullinax JE, Sarnaik AA, Sondak VK, Perez MC, Zager JS. The Use of Radar-Guided Localization to Identify Metastatic Melanoma After Neoadjuvant Immunotherapy. Ann Surg Oncol. 2025 Jul.32(7):5300-5305. Pubmedid: 40279056.
• Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Luan D, Bachanova V, Badar T, Bar M, Barba P, Beitinjaneh AM, Cashen A, Dholaria B, Elsawy M, Ganguly S, Geethakumari PR, Greenbaum U, Hashmi H, Hill LC, Jain MD, Jain T, Kebriaei P, Kittai AS, Locke FL, Lulla PD, Mead E, McGuirk JP, Mussetti A, Nishihori T, Olson AL, Pennisi M, Perales MA, Riedell PA, Saber W, Mirza AS, Magalhaes-Silverman M, Shpall EJ, Sorror M, Wudhikarn K, Turtle CJ, Moskop A, Pasquini MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul.31(7):419-433. Pubmedid: 40288610.
• Vasu S, Zhao Q, Miller EG, Elder P, Langenberg L, Cataland SR, Davies SM, Bejanyan N, Hahn T. High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS Consortium study. Blood. 2025 Jul.146(5):638-646. Pubmedid: 40300075.
• van der Burg SJC, Fiore M, Rutkowski P, Albertsmeier M, Bonvalot S, Grignol VP, Raut CP, Cananzi FCM, Mullinax JE, Gyorki DE, Pennacchioli E, Ford SJ, Nessim C, Cardona K, Callegaro D, Skoczylas J, Lindner LH, Gronchi A, Van Houdt WJ. Radiologic and Pathologic Response Evaluation After Neoadjuvant Chemotherapy for Primary Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Collaboration. Ann Surg Oncol. 2025 Jul.32(7):5359-5366. Pubmedid: 40374864.
• Flaherty KT, Aplin AE, Davies MA, Hacohen N, Herlyn M, Hoon D, Hwu P, Lotem M, Mulé J, Wargo JA, Fisher DE. Facts and Hopes: Toward the Next Quantum Leap in Melanoma. Clin Cancer Res. 2025 Jul.31(14):2882-2889. Pubmedid: 40407722. Pmcid: PMC12240026.
• Chafe SC, Zhai K, Aghaei N, Miletic P, Huang Z, Brown KR, Mobilio D, Young D, Suk Y, Grewal S, McKenna D, Alizada Z, Kieliszek AM, Lam FC, Escudero L, Huang Q, Huebner A, Lu J, Ang P, Anand A, Custers S, Apel E, Slassi S, Brakel B, Kim J, Liu JKC, Bassey-Archibong BI, Abdo R, Shargall Y, Lu JQ, Cutz JC, Zhang Q, Li SS, Venugopal C, Hynds RE, Dufour A, Moffat J, Swanton C, Bao S, Singh SK. A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis. Sci Transl Med. 2025 Jul.17(805):eadu2459. Pubmedid: 40601773. Pmcid: PMC7617989.
• Hoskins EL, Vella R, Reeser JW, Wing MR, Samorodnitsky E, Turkoglu A, Stein L, Breuning E, Risch ZA, Hernandez-Sanchez WM, Yu L, Churchman M, Single N, Chahoud J, Jimeno A, Cavnar MJ, Reilley M, Scaife C, Nepple KG, Phan M, Schneider B, Edge S, Salhia B, Leiser A, Wise-Draper TM, Wendt MK, Roychowdhury S. Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers. NPJ Precis Oncol. 2025 Jul.9(1):221. Pubmedid: 40610725. Pmcid: PMC12229568.
• DaCosta-Clark T, Kale B, Perna F. On the Road to Safer CAR Therapy for B-Cell Lymphoma: Real-World Evidence. Transplant Cell Ther. 2025 Jul.31(7):401-404. Pubmedid: 40617680.
• Jimenez Jimenez AM, Spellman SR, Politikos I, McCurdy SR, Devine SM, Malki MMA, Bolon YT, Lee SJ, Dehn J, Pidala J, Maiers M, Askar M, Malmberg C, Auletta JJ, Stefanski H, Broglie L, Qayed M, Horwitz M, Wilder JS, Gooptu M, Mehta RS, Fernandez-Viña M, Shaw BE, Shaffer BC. Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Transplant Cell Ther. 2025 Jul. Pubmedid: 40619101. Pmcid: PMC12344661.
• Veith T, Beck R, Tagal V, Li T, Alahmari S, Cole J, Hannaby D, Kyei J, Yu X, Maksin K, Schultz A, Lee H, El Naqa I, Eschrich S, Ji HP, Diaz A, Andor N. CLONEID: A Framework for Longitudinal Integration of Phenotypic and Genotypic Data to Monitor and Steer Subclonal Dynamics. bioRxiv. 2025 Jul. Pubmedid: 40631300. Pmcid: PMC12236826.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica. 2025 Jul. Pubmedid: 40637727.
• Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025 Jul.31(7):2132-2146. Pubmedid: 40670774.
• Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Rec. Int J Radiat Oncol Biol Phys. 2025 Jul. Pubmedid: 40685017.
• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2025 Jul. Pubmedid: 40716995.
• Pichler R, van Creij NCH, Mertens LS, Del Giudice F, Koll F, Soria F, Subiela JD, Plage H, Tymoszuk P, Mayr R, Klinglmair G, Seeber A, Pichler M, Günther M, Ormanns S, Compérat E, Li R, Moschini M, Pradére B. FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma. Eur Urol Oncol. 2025 Jul. Pubmedid: 40716983.
• Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, Mohammad TJ, Bachmeier CA, Naderinezhad S, Reid K, Corallo S, Yoder SJ, Zhang C, Zhang L, Miranda JA, Shah B, Chavez JC, Hesterberg RS, Delgado LC, Savid-Frontera C, Rodriguez PC, Cleveland JL, Wang X, Davila ML, Locke FL. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer. 2025 Jul.13(7). Pubmedid: 40730421. Pmcid: PMC12306477.
• Feng Y, Yuan Q, Zuniga A, Islam S, Avram D, Guryanova OA. Optimized Mouse Model to Induce Colitis-Associated Colon Cancer using Azoxymethane and Dextran Sulfate Sodium for Tumor Immunology and Therapy Studies. J Vis Exp. 2025 Jul.(221). Pubmedid: 40788861.
• Gallagher K, Sousa RS, Gatenbee C, Schenck R, Chen P, Citak T, Leither S, Mazzacurati L, Xella A, Zhou Z, Lemanne D, Rodriguez P, George E, Strobl MAR. Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy. bioRxiv. 2025 Jul. Pubmedid: 40791474. Pmcid: PMC12338546.
• Srivastava J, Yadav VK, Jimenez RV, Phadatare PR, Inamdar NA, Young MM, Bacchiocchi A, Halaban R, Fang B, Pulido AM, Tsai KY, Smalley KSM, Koomen JM, Rodriguez PC, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Res. 2025 Jun.85(12):2268-2287. Pubmedid: 40287947. Pmcid: PMC12167936.
• Jain MD, Abramson JS, Ansell SM. Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies. Am Soc Clin Oncol Educ Book. 2025 Jun.45(3):e473916. Pubmedid: 40294348.
• Mehta RS, Choe H, Saultz J, Gong Z, Sharma P, Al-Juhaishi T, Petitto GS, Lazaryan A, Singh A, Xue E, Dimitrova D, Hyder M, McCurdy S, Im A, Huber B, Aljawai YM, Kanakry J, Milano F, Kanakry CG. Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. Am J Hematol. 2025 Jun.100(6):987-997. Pubmedid: 40071498.
• Freeman CL, Srinivasan S, Hodkinson B, Deshpande S, Henninger T, Boyle M, Wang ML, Dreyling M, Scott DW. Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status. Blood. 2025 Jun.145(25):3052-3056. Pubmedid: 40101138.
• Lust H, Schultz LM, Kwon S, Roloff GW, Aldoss I, Baggott C, John S, Rossoff J, McNerney KO, Fabrizio VA, Talano JA, Moskop A, Curran KJ, Phillips CL, Karras NA, Baumeister SHC, Cooper S, Hermiston ML, Satwani P, Qayed M, Raikar SS, MacMillan ML, Hall EM, Nguyen K, Cassaday RD, Kopmar NE, Kota VK, Mathews J, Shaughnessy PJ, Schwartz MS, Ladha A, Yaghmour G, Kumaran M, Bachanova V, Tracy SI, Othman T, Luskin MR, Chen EC, Advani AS, Jeyakumar N, Miller K, Zhang A, Shah BD, Muffly LS, Faramand RG. Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025 Jun.9(11):2763-2772. Pubmedid: 40127395. Pmcid: PMC12166372.
• Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman M. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun.145(23):2762-2767. Pubmedid: 39938007.
• Locke FL, Mahmoudjafari Z, Kebriaei P, Gardner RA, Frigault MJ, Frey N, Komanduri KV, Perales MA, Nikiforow S. Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplant Cell Ther. 2025 Jun.31(6):349.e1-349.e12. Pubmedid: 39954962.
• Ugolini A, De Leo A, Yu X, Scirocchi F, Liu X, Peixoto B, Scocozza D, Pace A, Perego M, Gardini A, D'Angelo L, Liu JKC, Etame AB, Rughetti A, Nuti M, Santoro A, Vogelbaum MA, Conejo-Garcia JR, Rodriguez PC, Veglia F. Functional Reprogramming of Neutrophils within the Brain Tumor Microenvironment by Hypoxia-Driven Histone Lactylation. Cancer Discov. 2025 Jun.15(6):1270-1296. Pubmedid: 40014923. Pmcid: PMC12133432.
• Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, Lin Y, Lunning MA, Hill BT, Ghobadi A, Hu ZH, Hemmer MT, Zoratti MJ, Vunnum S, Tsang J, Spooner C, Smith H, Fu C, Patel AR, Miao H, Shahani SA, Mirjah DL, Xu H, Pasquini MC. Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025 Jun.9(11):2663-2676. Pubmedid: 39883946. Pmcid: PMC12155625.
• Carpinito GP, Gerald T, Hensley PJ, Martin AJ, Pallauf M, Pham J, Li R, Potretzke AM, Spiess PE, Singla N, Raman JD, Coleman J, Matin SF, Margulis V. The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN). Urol Oncol. 2025 Jun.43(6):390.e1-390.e11. Pubmedid: 39721824.
• Buro AW, Irizarry Gatell V, Fulton HJ, Blackwell R, Geiss C, Li X, Zambrano K, Rodriguez Y, Faramand R, Oswald LB. Sexual Health Among Young Adults Treated with Chimeric Antigen Receptor T Cell Therapy: A Mixed-Methods Study. J Adolesc Young Adult Oncol. 2025 Jun.14(3):244-252. Pubmedid: 39527302. Pmcid: PMC12223386.
• Leyderman M, Chandrasekar T, Grivas P, Li R, Bhat S, Basnet A, Shapiro O, Jacob J, Daneshvar MA, Kord E, Bratslavsky G, Goldberg H. Metastasis development in non-muscle-invasive bladder cancer. Nat Rev Urol. 2025 Jun.22(6):375-386. Pubmedid: 39567681.
• Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Finckenstein FG, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA. Long-term Efficacy and Safety of Lifileucel Tumor-infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Melanoma: A 5-year Analysis of the C-144-01 Study. J Clin Oncol. 2025 Jun. Pubmedid: 40454684.
• Gao Y, Yin Q, Gamallat Y, Grant MG, Snell AH, Shi X, Ulstad LN, Singh A, Chen T, Johnson JO, Avram D, Wan L. Linear ubiquitination of p31comet by HOIP couples cytokine response with mitotic regulation. Cell Biosci. 2025 Jun.15(1):75. Pubmedid: 40462232. Pmcid: PMC12135451.
• Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 2025 Jun.10(6):105312. Pubmedid: 40499462. Pmcid: PMC12182777.
• Jazayeri SB, Fazili A, Sirard RB, Zemp L, Johnstone PAS, Chahoud J, Spiess PE. Outcomes of PeIN at the surgical margin: insights from an organ-sparing penile cancer database. World J Urol. 2025 Jun.43(1):360. Pubmedid: 40478443.
• Xu X, Liu X, Dollar JJ, Liu X, Jasani N, Posorske B, Sriramareddy SN, Jarajapu V, Kuznetsoff JN, Sinard J, Bennett RL, Licht JD, Smalley KSM, Harbour JW, Yu X, Karreth FA. A multi-step immune-competent genetic mouse model reveals phenotypic plasticity in uveal melanoma. bioRxiv. 2025 Jun. Pubmedid: 40502063. Pmcid: PMC12157397.
• Tirotta F, Fiore M, Bonvalot S, Strauss D, Rutkowski P, Gyorki DE, van Houdt WJ, Callegaro D, Albertsmeier M, Tzanis D, Cananzi F, Sicklick JK, Mullinax J, Wilkinson M, Grignol VP, Cardona K, Bouhadiba T, Novak M, Valeri S, Fairweather M, Ford SJ, Skoczylas J, Snow H, Hayes AJ, Hodson J, Raut CP, Gronchi A. Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter study. EClinicalMedicine. 2025 Jun.84:103280. Pubmedid: 40521170. Pmcid: PMC12167443.
• Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun.9:e2400776. Pubmedid: 40526879. Pmcid: PMC12184982.
• Emens LA, Moussion C, Hwu P, Gulley JL, Ohashi PS, Bifulco CB, Feltquate D. SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development. J Immunother Cancer. 2025 Jun.13(6). Pubmedid: 40550567. Pmcid: PMC12184391.
• Dent J, Jorge M, Sobrevilla N, Uldrick TS, Adoubi I, Bajpai J, Burotto M, Bulhan H, Dosunmu GT, Ekpo L, Gopal S, Espinoza-Gutarra MR, Homian NM, Kingham TP, Mathias C, Ngwa W, Niyonzima N, Nkegoum B, Olopade OI, Odeny TA, Posey AD, Sahebjam S, Switzer R, Tarhini AA, Vanderpuye V, Kaufman DR. Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee. J Immunother Cancer. 2025 Jun.13(6). Pubmedid: 40550565. Pmcid: PMC12184393.
• Obertopp N, Bekker RA, Grass GD, Zelenka T, Thomas A, Potez M, Ali J, Blauvelt J, Hall AM, Hall MS, Chung CH, Enderling H, Pilon-Thomas S. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes. Int J Radiat Oncol Biol Phys. 2025 Jun. Pubmedid: 40582598.
• Parajuli B, Midya V, Kiddle R, De Jager N, Eggers S, Spakowicz D, Hoyd R, Salhia B, Chan CHF, Churchman ML, Rounbehler RJ, Yao S, Rutkowski MR, Tarhini AA, Mudaranthakam DP, Masood A, Bocklage TJ, Lentz RW, Hatoum H, Ilozumba MN, Hardikar S, Ulrich CM, Round JL, Riedlinger G, Shriver CD, Bosch DE. Primary tumor microbiomes predict distant metastasis of colorectal cancer. bioRxiv. 2025 Jun. Pubmedid: 40661479. Pmcid: PMC12258887.
• Xu X, Chadourne M, Soto-Vargas Z, Jarajapu V, Yao J, Yu X, Karreth FA. FRA1 drives melanoma metastasis through an actionable transcriptional network. bioRxiv. 2025 Jun. Pubmedid: 40661443. Pmcid: PMC12258986.
• Doerfler R, Chen J, Kim C, Smith JD, Harris M, Singh KB, Isett B, Dadey RE, Brown DD, Lee AV, Wang X, Spector ME, Kim S, Sridharan S, Contrera K, Smith K, Reeder C, Lyons M, Luo J, Liu S, Zandberg DP, Skinner HD, Zervantonakis IK, Vujanović L, Ferris RL, Seethala RR, Zevallos JP, Luke JJ, Bao R. Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck Cancer. bioRxiv. 2025 Jun. Pubmedid: 40667087. Pmcid: PMC12262215.
• Jazayeri B, Li R. Personalized neoantigen vaccines in urologic malignancies. Nat Cancer. 2025 Jun.6(6):916-918. Pubmedid: 40346293.
• Mansilla-Soto J, Milone MC. Concept CARs are picking up speed. Mol Ther. 2025 Jun.33(6):2363-2367. Pubmedid: 40340247. Pmcid: PMC12172278.
• Milone MC, Mansilla-Soto J, Pardi N, George LA, Byrne BJ, Herzog RW. Clinical advances in gene, cell, and RNA therapies. Mol Ther. 2025 Jun.33(6):2311. Pubmedid: 40398418. Pmcid: PMC12172262.
• Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May.39(5):1058-1068. Pubmedid: 40108332. Pmcid: PMC12055586.
• Eljilany I, Garcia JR, Jamal B, Tarhini AA. Monoclonal antibodies as adjuvant therapies for resected melanoma. Expert Opin Biol Ther. 2025 May.25(5):1-14. Pubmedid: 40125987.
• Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers JJ, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP. Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv. 2025 May.9(10):2511-2529. Pubmedid: 39938006. Pmcid: PMC12148389.
• Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, Stevens DA, Malik SA, Shouse GP, Hamadani M, Oluwole OO, Perales MA, Miklos DB, Fisher PW, Feng A, Navale L, Le Gall JB, Neelapu SS. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol. 2025 May.43(14):1695-1705. Pubmedid: 39946666. Pmcid: PMC12058369.
• Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 May.43(13):1597-1609. Pubmedid: 39965175. Pmcid: PMC12037312.
• Coghill AE, Van Bibber N, Baiocchi RA, Arnold SM, Riedlinger G, Schneider BP, Zhang Y, Suneja G, Gomez Fontela M, Abate-Daga D, Teer JK. Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN). Cancer Epidemiol Biomarkers Prev. 2025 May.34(5):774-779. Pubmedid: 40019488. Pmcid: PMC12048233.
• Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez JC. Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone Marrow Transplant. 2025 May.60(5):632-639. Pubmedid: 40025178.
• D'Angelo SP, Druta M, Van Tine BA, Liebner D, Schuetze SM, Tap WD, Preston J, Goodison S, D'Souza JW, Kapoor GS, Suchindran S, Zajic S, Bhaskar A, Kaczynski H, Kim J, Klohe E, Corigliano E, Eleftheriadou I, Nathenson MJ, Somaiah N. Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma. J Clin Oncol. 2025 May.43(15):1777-1788. Pubmedid: 39836945. Pmcid: PMC12084024.
• Hendrick LE, Naffouje S, Imanirad I, Pereira AL, Biachi T, Sanchez J, Dessureault S, Stefanou A, Dineen SP, Felder S. Incomplete Resection Is Twice as Likely in Locally Advanced Mucinous Compared to Nonmucinous Rectal Adenocarcinoma: A National Propensity-Matched Analysis. J Surg Oncol. 2025 May.131(6):1090-1100. Pubmedid: 39658830.
• Scilipoti P, Moschini M, Li R, Lerner SP, Black PC, Necchi A, Rouprêt M, Shariat SF, Gupta S, Morgans AK, Psutka SP, Kamat AM. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2025 May.87(5):536-550. Pubmedid: 39730299.
• Buchbinder E, Lotze MT, Margolin KA, Amaria R, Sarnaik A, Seery V, Eroglu Z, Khaddour K, Betof Warner A, Kluger HM, Sznol M, Atkins MB, Mcdermott DF, Silk AW. Role of high-dose interleukin-2 for melanoma in the age of cellular therapy. J Immunother Cancer. 2025 May.13(5). Pubmedid: 40447314. Pmcid: PMC12128428.
• Balagurunathan Y, Choi JW, Thompson Z, Jain M, Locke FL. Radiomic Features Prognosticate Treatment Response in CAR-T Cell Therapy. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507312. Pmcid: PMC12153729.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Identification of an Immune-Related Gene Signature for Prognostic Prediction in Glioblastoma: Insights from Integrated Bulk and Single-Cell RNA Sequencing. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507280. Pmcid: PMC12153616.
• Alonso-Matilla R, Pedro DI, Pepe A, Serrano-Velez J, Dunne M, Nguyen DT, Sawyer WG, Provenzano PP, Odde DJ. Biophysical modeling identifies an optimal hybrid amoeboid-mesenchymal mechanism for maximal T cell migration speeds. bioRxiv. 2025 Sep. Pubmedid: 39026744. Pmcid: PMC11257493.
• Soupir A, Ospina OE, Hampton O, Churchman M, Radmacher M, Hedges D, McKean D, Agius P, Zeeshan S, Seligson ND, Pollock R, Liebner D, Chen JL, Tinoco G, Salhia B, McCarter M, Wilky BA, Miller BJ, Cavnar MJ, Groundland JS, Schneider BP, Riedlinger G, Edge SB, Moskaluk CA, Cardona K, Naqash AR, Gonzalez RJ, Mullinax JE, Joyce DM, Binitie O, Douglas Letson G, Naghavi AO, Druta M, Reed DR, Siegel EM, Teer JK, Fridley BL, Brohl AS. Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. Nat Commun. 2025 May.16(1):4206. Pubmedid: 40328759. Pmcid: PMC12055966.
• Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025 May.15(1):92. Pubmedid: 40346049. Pmcid: PMC12064690.
• Wang C, Yu X, Teer JK, Yao J, Du D, Liu X, Thompson ZJ, Wang MH, Welsh EA, Memon D, Chan TA, Makarov V, Anadon CM, Saeed L, Boyle TA, Fang B, Koomen JM, Cox C, Landin AM, Yoder SJ, Kim S, Chen DT, Pilon-Thomas SA, Conejo-Garcia JR, Antonia SJ, Haura EB, Creelan BC. Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy. Nat Cancer. 2025 May.6(5):801-819. Pubmedid: 40341231.
• Chahoud J, Spiess PE. Authors' Reply to the Letter to the Editor by May et al: Optimized Prognostic Stratification in PSCC. J Natl Compr Canc Ne. 2025 May.23(5). Pubmedid: 40340844.
• Locke FL, Ball G, Ray MD, Li T, Limbrick-Oldfield EH, Popoff E, Kanters S. Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND. Hematol Oncol. 2025 May.43(3):e70100. Pubmedid: 40347097. Pmcid: PMC12065393.
• Robinson TJ, Liveringhouse CL, Wilson C, Friedman S, Nakashima J, Mills MN, Purcell JD, Figura NB, Dongliang D, Thapa R, Welsh E, Ahmed KA, Grass GD, Fridley BL, Diaz R. Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets. Breast Cancer Res. 2025 May.27(1):77. Pubmedid: 40361136. Pmcid: PMC12070507.
• Ahmed KA, Quick AM, Chon HS, Chern JY, Bixel K, Kim Y, Li J, Montejo ME, Dowell RA, Kim S, Fernandez DC, Lam CA, Hakam A, Rosa M, Shafique M, Shahzad MM, Wenham RM. Atezolizumab and Stereotactic Body Radiation in Metastatic, Recurrent, or Persistent Cervical Cancer: Results From a Phase 2 Multi-Institutional Study. Int J Radiat Oncol Biol Phys. 2025 May. Pubmedid: 40379142.
• Henning JE, Nishihori T, Freeman C, Lazarides A, Song J, Kuruvilla D, Feuerlein S, Costello JR. Whole-body MRI for a patient with progressive multiple myeloma. BJR Case Rep. 2025 May.11(3):uaaf028. Pubmedid: 40386466. Pmcid: PMC12085220.
• Pusztai L, Sondak VK, Aguiar-Ibáñez R, Cappuzzo F, Chouaid C, Elder C, Hirasawa Y, Ishida M, Jones R, Lee SH, Mizuno R, Nagata M, Okonji D, Parente P, Shah B, Sun A, Ferreira D, Spiteri C, Lauer A, Kaliasethi A, Kao C, Kothari S, McKendrick J. Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study. J Immunother Cancer. 2025 May.13(5). Pubmedid: 40425232. Pmcid: PMC12107590.
• Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. Bull Math Biol. 2025 May.87(7):86. Pubmedid: 40434675. Pmcid: PMC12279038.
• Song X, Yu X, Moran-Segura CM, Xu H, Li T, Davis JT, Vosoughi A, Grass GD, Li R, Wang X. ROICellTrack: a deep learning framework for integrating cellular imaging modalities in subcellular spatial transcriptomic profiling of tumor tissues. Bioinformatics. 2025 May.41(5). Pubmedid: 40199763. Pmcid: PMC12085996.
• Ramamoorthi G, Lee MC, Farrell CM, Snyder C, Garg SK, Aldrich AL, Lok V, Dominguez-Viqueira W, Olson-Mcpeek SK, Rosa M, Gautam N, Pilon-Thomas S, Cen L, Kodumudi KN, Wiener D, Oskarsson T, Gomes AP, Gatenby RA, Czerniecki BJ. Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. Cancer Immunol Res. 2025 May.13(5):729-748. Pubmedid: 40249209. Pmcid: PMC12046335.
• Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani NI, Hegde U, Cohen J, Sznol M, Anderson G, Johnson B, Piteo C, Mahajan A, Adeniran A, Jilaveanu L, Goldberg S, Chiang V, Forsyth P, Kluger HM. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. J Clin Oncol. 2025 May.43(14):1685-1694. Pubmedid: 40048689. Pmcid: PMC12058415.
• Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. 2025 May.9(9):2336-2340. Pubmedid: 40088469. Pmcid: PMC12127628.
• Renatino Canevarolo R, Sudalagunta PR, Meads MB, Silva M, Zhao X, Magaletti D, Alugubelli RR, DeAvila G, Persi E, Maura F, Bell ET, Bishop RT, Cubitt CL, Sansil SS, Zhang W, Teer JK, Teng M, Yoder SJ, Siegel EM, Shah BD, Nishihori T, Hazlehurst LA, Lynch CC, Landgren O, Hampton O, Gatenby RA, Sullivan DM, Brayer JB, Dalton WS, Cleveland JL, Alsina M, Baz R, Shain KH, Silva AS. Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Res Sq. 2025 Apr. Pubmedid: 40321765. Pmcid: PMC12048002.
• Baumrucker CC, Harris N, Hoover S, Czerniecki BJ. Intratumoral Immunotherapy in Breast Cancer. Vaccines (Basel). 2025 Apr.13(4). Pubmedid: 40333343. Pmcid: PMC12031351.
• Mokhtari S, Asquith JM, Kareem SS, Bachmeier CA, Pina Y, Faramand RG, Kim Y, Peguero EN, Sahebjam S, Jaffer MH, Iacono DP, Jain MD, Vogelbaum MA, Davila ML, Forsyth PA, Locke FL, Lazaryan A. Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Int J Mol Sci. 2025 Apr.26(8). Pubmedid: 40332772. Pmcid: PMC12028060.
• Jain MD. Prolonged Neurologic Symptoms After CAR T Cell Therapy - What Is It?. Transplant Cell Ther. 2025 Apr.31(4):190-191. Pubmedid: 40159020.
• Mishra A, Thapa R, Bigam K, Extermann M, Faramand R, Khimani F, Wang X, Baracos V, Pidala JA. Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease. J Cachexia Sarcopenia Muscle. 2025 Apr.16(2):e13759. Pubmedid: 40151989. Pmcid: PMC11950734.
• Rossetti RAM, Tordesillas L, Beatty MS, Cianne J, Martinez Planes E, Du D, Snedal S, Wang C, Perez BA, Berglund A, Chen YA, Sarnaik A, Mulé JJ, Creelan B, Pilon-Thomas S, Abate-Daga D. CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. J Immunother Cancer. 2025 Apr.13(4). Pubmedid: 40199608. Pmcid: PMC11979601.
• Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: 40229239. Pmcid: PMC11997198.
• Faramand R, Muffly L. Humanizing CAR T-cell therapy in B-ALL. Blood Adv. 2025 Apr.9(8):1916-1917. Pubmedid: 40214999. Pmcid: PMC12011161.
• Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2025 Apr. Pubmedid: 40268594.
• Ahmed KA, Kim Y, Kim S, Wang MH, DeJesus M, Arrington JA, Soyano AE, Armaghani AJ, Costa RLB, Loftus LS, Rosa M, Caudell JJ, Diaz R, Etame AB, Tran ND, Soliman H, Czerniecki BJ, Forsyth PA, Yu HM, Han HS. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. J Immunother Cancer. 2025 Apr.13(4). Pubmedid: 40295143. Pmcid: PMC12039042.
• El Jurdi N, Hamilton BK, Pidala JA, Onstad L, Mun C, Jain S, Lee SJ. Longitudinal Tear Cytokine Biomarkers: An Analysis from the Close Assessment and Testing for Chronic Graft-Versus-Host Disease (CATCH) Protocol. Transplant Cell Ther. 2025 Apr.31(4):226.e1-226.e9. Pubmedid: 39923937. Pmcid: PMC11957925.
• Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702. Leukemia. 2025 Apr.39(4):1001-1004. Pubmedid: 39994463. Pmcid: PMC11978488.
• Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Gershenwald JE, Sondak VK. Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial. Ann Surg Oncol. 2025 Apr.32(4):2756-2764. Pubmedid: 39893343.
• Barata PC, Zarrabi KK, Bex A, Grivas P, Hermann K, Hofman MS, Li R, Lopez-Beltran A, Padani AR, Powles T, Taplin ME, Loriot Y. Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. Eur Urol. 2025 Apr.87(4):412-423. Pubmedid: 39638730.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Wahlstedt ER, Varadhan AK, Wahlstedt JC, Coughlin E, Perisetla N, Mhaskar R, Bilotta A, Nguyen D, Gilbert SM, Li R, Spiess PE, Huelster HL. Effects of Socioeconomic Deprivation on UTUC Staging, Mortality, and Recurrence. Urology. 2025 Apr.198:58-65. Pubmedid: 39674377.
• Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: 39786391. Pmcid: PMC11986210.
• de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Naryan V, Gibb EA, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Lotan Y. A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. BJU Int. 2025 Apr.135(4):648-656. Pubmedid: 39485082. Pmcid: PMC11913596.
• Baumrin E, Pidala JA, Mitchell S, Onstad L, Lee SJ. Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis. Blood. 2025 Mar.145(12):1321-1332. Pubmedid: 39808799. Pmcid: PMC11952005.
• Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, Debruyne PR, Fox JR, Gambardella V, Gil-Martin M, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Olawaiye AB, Pothuri B, Reck M, Sudo K, Sunakawa Y, Van Marcke C, Yu EY, Ramos J, Tan S, Bieda M, Stinchcombe TE, Pohlmann PR. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025 Mar.31(3):909-916. Pubmedid: 39825152. Pmcid: PMC11922774.
• Short NJ, Aldoss I, DeAngelo DJ, Konopleva MY, Leonard JT, Logan A, Park JH, Shah BD, Stock W, Jabbour EJ. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood Adv. 2025 Mar.9(6):1442-1451. Pubmedid: 39853316. Pmcid: PMC11960638.
• Ospina OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, Smalley I, Tsai KY, Markowitz J, Vallebuona E, Berglund AE, Eschrich SA, Yu X, Fridley BL. spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis. Cancer Res. 2025 Mar.85(5):848-858. Pubmedid: 39636739. Pmcid: PMC11873723.
• Senent Y, Remírez A, Repáraz D, Llopiz D, Celias DP, Sainz C, Entrialgo-Cadierno R, Suarez L, Rouzaut A, Alignani D, Tavira B, Lambris JD, Woodruff TM, de Andrea CE, Ruffell B, Sarobe P, Ajona D, Pio R. The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response. Cancer Immunol Res. 2025 Mar.13(3):384-399. Pubmedid: 39666368.
• Hoogland AI, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, Oswald LB, Snider JT, Wade SW, Chavez J, Corallo S, Booth-Jones M, Jain MD, Locke FL, Jim HSL. Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene Ciloleucel. Transplant Cell Ther. 2025 Mar.31(3):157.e1-157.e13. Pubmedid: 39733840.
• Choi JI, Freedman GM, Guttmann DM, Ahmed K, Gao W, Walker EM, Harris EE, Gonzalez V, Ye J, Nead K, Taunk N, Tadros AB, Dang CT, Daroui P, Novick K. Executive Summary of the American Radium Society Appropriate Use Criteria: Regional Nodal Irradiation for Breast Cancer. Am J Clin Oncol. 2025 Mar.48(3):111-121. Pubmedid: 39761648.
• Pidala JA, Kim J, Kalos D, Cutler CS, DeFilipp Z, Flowers ME, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko CL, Ponce DM, Sung AD, Tang H, Farhadfar N, Nemecek ER, Pusic I, Qayed M, Rangarajan HG, Hogan WJ, Etra AM, Jaglowski SM. Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis. Blood Adv. 2025 Mar.9(5):1040-1048. Pubmedid: 39454280. Pmcid: PMC11909441.
• Andrew TW, Erdmann S, Alrawi M, Plummer R, Shalhout SZ, Sondak V, Brownell I, Lovat PE, Rose A. A multivariable disease-specific model enhances prognostication beyond current Merkel cell carcinoma staging: An international cohort study of 10,958 patients. J Am Acad Dermatol. 2025 Mar.92(3):520-527. Pubmedid: 39577698.
• Sargen MR, Barnhill RL, Elder DE, Swetter SM, Prieto VG, Ko JS, Bahrami A, Gerami P, Karunamurthy A, Pappo AS, Schuchter LM, LeBoit PE, Yeh I, Kirkwood JM, Jen M, Dunkel IJ, Durham MM, Christison-Lagay ER, Austin MT, Aldrink JH, Mehrhoff C, Hawryluk EB, Chu EY, Busam KJ, Sondak V, Messina J, Puig S, Colebatch AJ, Coughlin CC, Berrebi KG, Laetsch TW, Mitchell SG, Seynnaeve B. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol. 2025 Mar.43(9):1157-1167. Pubmedid: 39365959. Pmcid: PMC11908957.
• Guske C, Jazayeri SB, Li R. Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027. Eur Urol. 2025 Mar.87(3):e54-e55. Pubmedid: 39406614.
• Smith HR, Horta M, Dougan SO, Washington SJ, Yates HC, Pidala J, Reblin M, Jim H, Sutton SK, Vinci C. HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients. J Natl Compr Canc Ne. 2025 Mar.23(3.5). Pubmedid: 40157349.
• Davila M, Lee SB, Kang YP, Boucher J, Mandula J, Roselli E, Chang D, Jimenez R, Kotani H, Reid K, Vazquez-Martinez J, Beatty N, Goala P, Sierra-Mondragon R, Liu M, Koomen J, Nguyen J, Hussaini M, Shaw T, Wang X, Faramand R, Jain M, Locke F, Rodriguez P, Sailer C, McSain S, Hamid S, Tariq M, Wang J, Abraham-Miranda J. CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma. Res Sq. 2025 Mar. Pubmedid: 40235478. Pmcid: PMC11998770.
• Miyagi H, Yu X, Peak T, Dhillon J, Le C, Wang X, Yoder S, Marchion D, Lu X, Pettaway C, Moran Segura C, Zhang C, Roman Souza G, Yu A, Zemp L, Spiess P, Chahoud J. Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma. Sci Rep. 2025 Mar.15(1):7703. Pubmedid: 40044748. Pmcid: PMC11882776.
• Wang X, Li T, Slebos RJC, Chaudhary R, Guevara-Patino JA, Bonomi M, Saba NF, Chung CH. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunol Immun. 2025 Mar.74(4):142. Pubmedid: 40056190. Pmcid: PMC11890688.
• Rajagopal PS, Reid S, Fan R, Venton L, Weidner A, Roberson ML, Vadaparampil S, Wang X, Yoder S, Rosa M, Sanders M, Gonzalez-Ericsson P, Hirbo J, Whisenant JG, Pietenpol J, Ye F, Pal T, Lehmann BD. Population-specific patterns in assessing molecular subtypes of young black females with triple-negative breast cancer. NPJ Breast Cancer. 2025 Mar.11(1):28. Pubmedid: 40069179. Pmcid: PMC11897140.
• Molgora M, Colonna M. Targeting brain macrophages: NF-κB as a therapeutic gateway in melanoma brain metastasis. Cancer Cell. 2025 Mar.43(3):328-329. Pubmedid: 40068588.
• Takahashi H, Perez-Villarroel P, Falahat R, Mulé JJ. Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming. J Immunother Cancer. 2025 Mar.13(3). Pubmedid: 40081947. Pmcid: PMC11907082.
• Soliman H, Aldrich A, Abdo N, Han H, Soyano A, Costa R, Armaghani A, Kiluk J, Khakpour N, Lee MC, Hoover S, Laronga C, Niell B, Mooney B, Weinfurtner RJ, Rosa M, Czerniecki B. A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. NPJ Breast Cancer. 2025 Mar.11(1):29. Pubmedid: 40097486. Pmcid: PMC11914126.
• Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025 Mar.13(3). Pubmedid: 40102029. Pmcid: PMC11927433.
• Shah C, Vicini FA, Connolly EP, Rabinovitch RA, Czerniecki B, Mann GB, Whitworth PW, Mittal K, Shivers S, Bremer T. CLO25-061: 7-Gene Biosignature Reclassified Women With DCIS Meeting NCCN Guideline (RTOG 9804-Like) Low-Risk Criteria as Molecular High Risk. J Natl Compr Canc Ne. 2025 Mar.23(3.5). Pubmedid: 40154423.
• Faramand RG, Locke FL. Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. Nat Rev Clin Oncol. 2025 Mar.22(3):161-162. Pubmedid: 39930262.
• Berglund AE, Puskas J, Yoder SJ, Smith AT, Marchion DC, Qin D, Mulé JJ, Torres-Roca JF, Eschrich SA. Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory. Cancer Res Commun. 2025 Mar.5(3):389-397. Pubmedid: 39932296. Pmcid: PMC11873780.
• Mammadova J, Glass L, LaFave D, Pidala J, Lazaryan A. Elephantiasis nostra verrucosa in sclerodermatous chronic graft-versus-host disease. JAAD Case Rep. 2025 Mar.57:22-24. Pubmedid: 39936157. Pmcid: PMC11810717.
• de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Narayan V, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Gibb EA, Lotan Y. Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. Eur Urol Open Sci. 2025 Mar.73:24-30. Pubmedid: 39935941. Pmcid: PMC11810690.
• Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb.213(2):192-204. Pubmedid: 39383345.
• Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb.43(5):558-566. Pubmedid: 39418622.
• Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: 39924174. Pmcid: PMC11808862.
• Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, Cooper S, Dallas M, Oliveira S, Kelly K, Kitko C, Kohorst M, Kutny M, Lacayo N, Lee-Miller C, Ludwig K, Madden L, Maloney K, Mangum D, Massaro S, McCall D, Morocco P, Muller B, Murphy L, Nardi V, Rossoff J, Schuettpelz L, Shah B, Sun J, Wong V, Yanik G, Awotiwon A, Stehman K. Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Ne. 2025 Feb.23(2):41-62. Pubmedid: 39938467.
• Tebbi CK, Sahakian E, Shah B, Yan J, Mediavilla-Varela M, Patel S. Aspergillus flavus with Mycovirus as an Etiologic Factor for Acute Leukemias in Susceptible Individuals: Evidence and Discussion. Biomedicines. 2025 Feb.13(2). Pubmedid: 40002901. Pmcid: PMC11853382.
• Nagy MZ, Plaza-Rojas LB, Boucher JC, Kostenko E, Austin AL, Tarhini AA, Chen Z, Du D, Ojwang' AME, Davis J, Obermayer A, Rejniak KA, Shaw TI, Guevara-Patino JA. Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: 40010774.
• Han HS, Aldrich AL, Garg SK, Weinfurtner RJ, Nguyen JV, Mo Q, Whiting J, Childress J, Soliman H, Costa R, Armaghani A, Soyano A, Kiluk J, Hoover S, Lee MC, Khakpour N, Shenoi N, Jameel Z, Koski GK, Czerniecki BJ. Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2025 Feb.11(2):119-127. Pubmedid: 39636623. Pmcid: PMC11622104.
• Steinmetz AR, Jazayeri B, Pierce M, Mokkapati S, McConkey D, Li R, Dinney CP. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Feb.25(2):149-159. Pubmedid: 39779686.
• Locke FL, Westin JR, To C. Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma. Future Oncol. 2025 Feb.21(4):393-407. Pubmedid: 39800964. Pmcid: PMC11813213.
• Park SJ, Ellison DM, Weight R, Homsi J, Rabinowits G, Ruiz ES, Strasswimmer J, Simmons J, Panella T, Quek RG, Pouliot JF, Khushalani NI. CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. Future Oncol. 2025 Feb.21(4):431-436. Pubmedid: 39797702. Pmcid: PMC11812358.
• Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chia-Chi C, McDaniel LK, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang ML, Jain P, Nastoupil LJ, Westin JR, Arora R, Turner JG, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid KM, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Fahrmann J, Stein-Thoeringer C, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood. 2025 Feb.145(8):823-839. Pubmedid: 39441941.
• Alduaij W, Jiang A, Villa D, Collinge BJ, Ben-Neriah S, Boyle M, Meissner B, Hilton LK, Farinha P, Slack GW, Craig JW, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Sehn LH, Scott DW, Savage KJ. CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL. Blood. 2025 Feb.145(6):590-596. Pubmedid: 39441916.
• Dacoregio MI, Michelon I, Ernesto do Rego Castro C, Cezar Aquino de Moraes F, Rossato de Almeida G, Ravani LV, Vilbert M, Barros Costa RL. Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis. Breast. 2025 Feb.79:103853. Pubmedid: 39616817. Pmcid: PMC11648803.
• Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb.87(2):110-122. Pubmedid: 39353825.
• Vicini F, Shah C, Mittal K, Abraham J, Kruse M, Weinmann S, Leo M, Rabinovitch R, Wärnberg F, Whitworth PW, Czerniecki BJ, Shivers SC, Bremer T. A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy. Clin Breast Cancer. 2025 Feb.25(2):e152-e158.e1. Pubmedid: 39353799.
• Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol. 2025 Feb.43(4):403-411. Pubmedid: 39378386. Pmcid: PMC11776886.
• Sudalagunta PR, Canevarolo RR, Meads MB, Silva M, Zhao X, Cubitt CL, Sansil SS, DeAvila G, Alugubelli RR, Bishop RT, Tungesvik A, Zhang Q, Hampton O, Teer JK, Welsh EA, Yoder SJ, Shah BD, Hazlehurst L, Gatenby RA, Van Domelen DR, Chai Y, Wang F, DeCastro A, Bloomer AM, Siegel EM, Lynch CC, Sullivan DM, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Walker CJ, Landesman Y, Baz R, Silva AS, Shain KH. The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma. Cancer Res. 2025 Jan.85(2):378-398. Pubmedid: 39476082. Pmcid: PMC11733535.
• Farma JM, Olszanski AJ, Messina JL, Sondak VK. Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma. Ann Surg Oncol. 2025 Jan.32(1):3-11. Pubmedid: 39495363.
• Basile G, Bandini M, Li R, Poch MA, Necchi A, Spiess PE. Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma. Curr Opin Urol. 2025 Jan.35(1):75-82. Pubmedid: 39529478.
• DePalo DK, Dugan MM, Naqvi SMH, Ollila DW, Hieken TJ, Block MS, van Houdt WJ, Wouters MWJM, Reijers SJM, Asher N, Broman KK, Duncan Z, Anderson M, Gyorki DE, Snow H, Held J, Farma JM, Vetto JT, Hui JYC, Kolbow M, Saw RPM, Lo SN, Long GV, Thompson JF, Kim Y, Karapetyan L, Ny L, van Akkooi ACJ, Bagge RO, Zager JS. A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases. Cancer. 2025 Jan.131(1):e35636. Pubmedid: 39522025.
• Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mulé JJ, Conejo-Garcia JR. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan.31(1):176-188. Pubmedid: 39521884.
• Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jan.36(1):10-30. Pubmedid: 39550033.
• Bryant JM, Mills MN, Liveringhouse C, Palm R, Druta M, Brohl A, Reed DR, Johnstone PA, Miller JT, Latifi K, Feygelman V, Yang GQ, Naghavi AO. Hypofractionated accelerated radiation dose-painting (HARD) improves outcomes in unresected soft-tissue sarcoma. Radiother Oncol. 2025 Jan.202:110644. Pubmedid: 39571685.
• Shaw TI, Pounds S, Cao X, Ma J, Palacios G, Mason J, Perkins S, Wu G, Fan Y, Wang J, Zhou X, Obermayer A, Kinney MC, Kraveka J, Gross T, Sandlund J, Zhang J, Mullighan C, Lim MS, Leventaki V. Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma. Leukemia. 2025 Jan.39(1):199-210. Pubmedid: 39592809.
• Metts J, Rodriguez-Valentin M, Hensel J, Alfaro A, Snyder CW, Binitie O, Chebli C, Monforte H, Pilon-Thomas S, Mullinax J. Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors. Cytotherapy. 2025 Jan.27(1):29-35. Pubmedid: 39243253. Pmcid: PMC11668621.
• Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2025 Jan.209(1):147-159. Pubmedid: 39305392. Pmcid: PMC11785630.
• Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, Martin WG, Gross H, Akerley W, Hopkins JO, Patel SP, Sondak VK, Ribas A. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2025 Jan.131(1):e35587. Pubmedid: 39342463. Pmcid: PMC11694162.
• Garg A, Pena L, Lauwers GY, Druta M, Kis B. Radioembolization of Primary Splenic Angiosarcoma Complicated by Delayed Gastric Hemorrhage. J Vasc Interv Radiol. 2025 Jan.36(1):187-189.e1. Pubmedid: 39357601.
• Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan.145(1):85-97. Pubmedid: 39365257.
• Lazure F, Drapela S, Liu X, Lockhart JH, Kashfi H, Sarigul N, Ilter D, Flores ER, Wang X, Smalley I, Jaeger A, Yu X, Gomes AP. Aging directs the differential evolution of KRAS-driven lung adenocarcinoma. bioRxiv. 2025 Jan. Pubmedid: 39896625. Pmcid: PMC11785146.
• Bordeaux J, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, Bolotin D, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Ghosh K, Harms K, LeBoeuf N, Lukens JN, Manber S, Mark L, Medina T, Nehal KS, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha AR, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu YG, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Ne. 2025 Jan.23(1). Pubmedid: 39819674.
• Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med. 2025 Jan.14(2):e70594. Pubmedid: 39831734. Pmcid: PMC11744726.
• Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. bioRxiv. 2025 Jan. Pubmedid: 39829889. Pmcid: PMC11741369.
• Turcotte S, Donia M, Gastman B, Besser M, Brown R, Coukos G, Creelan B, Mullinax J, Sondak VK, Yang JC, Rohaan MW, Marie Svane I, Lotze MT, Haanen JBAG, Goff SL. Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment. J Immunother Cancer. 2025 Jan.13(1). Pubmedid: 39837618. Pmcid: PMC11752064.
• Miller JW, Johnson JS, Guske C, Mannam G, Hatoum F, Nassar M, Potez M, Fazili A, Spiess PE, Chahoud J. Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas. Cancers (Basel). 2025 Jan.17(2). Pubmedid: 39858107. Pmcid: PMC11763753.
• Adoncecchi G, Kumar A, Mogili K, Faramand R, Liu H, Khimani F, Mishra A, Nieder M, Nishihori T, Hansen D, Jain M, Lazaryan A, Perez L, Pidala J, Locke F, Anasetti C, Bejanyan N, Elmariah H. Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients. Cancers (Basel). 2025 Jan.17(2). Pubmedid: 39858092. Pmcid: PMC11763395.
• Kajihara R, Long MD, Hoki T, Chen H, Yamauchi T, Kanemaru H, Segal BH, Dy GK, Ito F. Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy. J Immunother Cancer. 2025 Jan.13(1). Pubmedid: 39863301. Pmcid: PMC11784231.
• Mustasam A, Parza K, Ionescu F, Gullapalli K, Paravathaneni M, Kim Y, Sandstrom RE, Al Assaad M, Grass GD, Johnstone P, Eschrich S, Safa H, Chadha J, Roman Souza G, David J, Semaan A, Zacharias NM, Pettaway C, Giuliano AR, Spiess PE, Chahoud J. The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis. J Natl Compr Canc Ne. 2025 Jan.23(2). Pubmedid: 39752880.
• Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea AM, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. Lancet Oncol. 2025 Jan.26(1):12-14. Pubmedid: 39756440.
• Andrew TW, Alrawi M, Plummer R, Reynolds N, Sondak V, Brownell I, Lovat PE, Rose A, Shalhout SZ. A hybrid machine learning approach for the personalized prognostication of aggressive skin cancers. NPJ Digit Med. 2025 Jan.8(1):15. Pubmedid: 39779875. Pmcid: PMC11711377.
• Chahoud J, Msaouel P. Belzutifan for renal cell carcinoma: Balancing regulatory approval with societal and patient impact. Med (N Y). 2025 Jan.6(1):100563. Pubmedid: 39798548.
• Piñero-Crespo G, Kucharik AH, Chen WS, Idiáquez DW, Doenges J, Zhang Y, Sokol L, Glass F. Cutaneous manifestations as the presenting signs of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements. JAAD Case Rep. 2025 Jan.55:23-26. Pubmedid: 39790106. Pmcid: PMC11714132.
• Kuilman T, Schrikkema DS, Gadiot J, Gomez-Eerland R, Bies L, Walker J, Spaapen RM, Kok H, Houg D, Viyacheva M, Claassen YB, Saornil M, Krijgsman O, Stringer B, Ding H, Geleijnse A, Meinema AC, Weissbrich B, Lancee M, Engele CG, Sabatino M, Chen PL, Tsai KY, Mulé JJ, Sondak VK, van den Bulk J, de Miranda NF, Jedema I, Haanen JG, van Heijst JWJ, Schumacher TN, Linnemann C, Bendle GM. Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. Nat Commun. 2025 Jan.16(1):649. Pubmedid: 39809767. Pmcid: PMC11733228.
• Wallis W, Gulbis AM, Wang T, Lee CJ, Sharma A, Williams KM, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem MM, MacMillan ML, Kitko CL, Pidala J, Spellman SR, Lee SJ, Alousi AM. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplant. 2025 Jan.60(1):52-57. Pubmedid: 39420192. Pmcid: PMC11724748.
• Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, Mullinax JE, Zager JS. ASO Visual Abstract: Isolated Limb Infusion for Limb Threatening Sarcomas. Ann Surg Oncol. 2025 Jan.32(1):568-569. Pubmedid: 39446227.
• Tejero JD, Hesterberg RS, Drapela S, Ilter D, Raizada D, Lazure F, Kashfi H, Liu M, Silvane L, Avram D, Fernández-García J, Asara JM, Fendt SM, Cleveland JL, Gomes AP. Methylmalonic acid induces metabolic abnormalities and exhaustion in CD8+ T cells to suppress anti-tumor immunity. Oncogene. 2025 Jan.44(2):105-114. Pubmedid: 39472497.
• Gillis N, Ebied A, Thompson ZJ, Pidala JA. Clinical impact of clonal hematopoiesis in hematopoietic cell transplantation: a review, meta-analysis, and call to action. Haematologica. 2024 Dec.109(12):3952-3964. Pubmedid: 38899345. Pmcid: PMC11609801.
• Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec.8(23):6139-6147. Pubmedid: 39093952. Pmcid: PMC11707416.
• Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec.86(6):516-527. Pubmedid: 39183090.
• Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. Cancer Discov. 2024 Dec.14(12):2509-2531. Pubmedid: 39189614. Pmcid: PMC11611684.
• Aflatooni S, Dugan MM, Boby A, Ghali H, DePalo DK, Naqvi SMH, Mullinax JE, Zager JS. Isolated Limb Infusion for Limb-Threatening Sarcomas. Ann Surg Oncol. 2024 Dec.31(13):9272-9280. Pubmedid: 39256312.
• Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, Varma A, McGuirk J, Dholaria BR, McCurdy SR, DeZern AE, Bejanyan N, Bashey A, Furst S, Castagna L, Mariotti J, Ruggeri A, Bailen R, Teshima T, Xiao-Jun H, Bonfim C, Aung F, Cao K, Carpenter PA, Hamadani M, Askar M, Fernandez-Vina M, Girnita A, Ciurea SO. ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies. Transplant Cell Ther. 2024 Dec.30(12):1139-1154. Pubmedid: 39260570.
• Dugan MM, Aflatooni S, Mullinax JE, Zager JS. ASO Author Reflections: Isolated Limb Infusion for Extremity Sarcomas: Past, Present, and Future. Ann Surg Oncol. 2024 Dec.31(13):9283-9284. Pubmedid: 39306620.
• Hoogland AI, Barata A, Li X, Irizarry-Arroyo N, Jain MD, Welniak T, Rodriguez Y, Oswald LB, Gudenkauf LM, Chavez JC, Khimani F, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Crowder SL, Parker NH, Carson TL, Vinci CE, Pidala JA, Logue J, Locke FL, Jim HSL. Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell Therapy. Transplant Cell Ther. 2024 Dec.30(12):1219.e1-1219.e11. Pubmedid: 39306278. Pmcid: PMC11635818.
• Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, Ghobadi A, Guerreiro M, Yallop D, Abedi M, Pantin JM, Yared JA, Beitinjaneh AM, Chaganti S, Hodby K, Menne T, Arellano ML, Malladi R, Shah BD, Mountjoy L, O'Dwyer KM, Peggs KS, Lao-Sirieix P, Zhang Y, Brugger W, Braendle E, Pule M, Bishop MR, DeAngelo DJ, Park JH, Jabbour E. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec.391(23):2219-2230. Pubmedid: 39602653.
• Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment. Genome Biol. 2024 Dec.25(1):308. Pubmedid: 39639369. Pmcid: PMC11622564.
• Aldoss I, Roboz GJ, Bassan R, Boissel N, DeAngelo DJ, Fleming S, Gökbuget N, Logan AC, Luger SM, Menne T, Park J, Schuh AC, Shah B, Jabbour E. Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia. Lancet Haematol. 2024 Dec.11(12):e959-e970. Pubmedid: 39638543.
• Reid S, Fan R, Venton L, Weidner A, Tezak A, Roberson ML, Vadaparampil S, Wang X, Yoder S, Rosa M, Hirbo J, Whisenant JG, Pietenpol J, Rajagopal PS, Lehmann B, Ye F, Pal T. West African Genetic Ancestry and Breast Cancer Outcomes Among Black Women. JAMA Netw Open. 2024 Dec.7(12):e2449798. Pubmedid: 39652347. Pmcid: PMC11629124.
• Eljilany I, Coleman S, Tan AC, McCarter MD, Carpten J, Colman H, Naqash AR, Puzanov I, Arnold SM, Churchman ML, Spakowicz D, Salhia B, Marin J, Ganesan S, Ratan A, Shriver C, Hwu P, Dalton WS, Weiner GJ, Conejo-Garcia JR, Rodriguez P, Tarhini AA. Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy. Cells. 2024 Dec.13(23). Pubmedid: 39682743. Pmcid: PMC11640164.
• Rosario SR, Long MD, Chilakapati S, Gomez EC, Battaglia S, Singh PK, Wang J, Wang K, Attwood K, Hess SM, McGray AJR, Odunsi K, Segal BH, Paragh G, Liu S, Wargo JA, Zsiros E. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat Commun. 2024 Dec.15(1):10609. Pubmedid: 39638782. Pmcid: PMC11621351.
• Iftikhar R, DeFilipp Z, DeZern AE, Pulsipher MA, Bejanyan N, Burroughs LM, Kharfan-Dabaja MA, Arai S, Kassim A, Nakamura R, Saldaña BJD, Aljurf M, Hamadani M, Carpenter PA, Antin JH. Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024 Dec.30(12):1155-1170. Pubmedid: 39307421.
• Timperi E, Croizer H, Khantakova D, Rana M, Molgora M, Guerriero JL, Mechta-Grigoriou F, Romano E. At the Interface of Tumor-Associated Macrophages and Fibroblasts: Immune-Suppressive Networks and Emerging Exploitable Targets. Clin Cancer Res. 2024 Dec.30(23):5242-5251. Pubmedid: 39311702.
• Liveringhouse C, Sim AJ, Zhang J, Jain RK, Naidu SU, Linkowski L, Zemp LW, Yu A, Sexton WJ, Spiess PE, Gilbert SM, Poch MA, Pow-Sang J, Li R, Manley BJ, Vosoughi A, Dhillon J, Xu H, Torres-Roca JF, Johnstone PAS, Yamoah K, Grass GD. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder. Clin Genitourin Cancer. 2024 Dec.22(6):102222. Pubmedid: 39353214.
• Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Brit J Haematol. 2024 Dec.205(6):2370-2375. Pubmedid: 39396814.
• Tarhini AA, Eroglu Z, Eljilany I, Zager JS, Gonzalez RJ, Sarnaik AA, Cruse CW, Khushalani NI, De Aquino DB, Abraham E, Acevedo DM, Richards A, Schell MJ, Kalos D, Chen PL, Messina JL, Canton DA, Sondak VK. Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma. Clin Cancer Res. 2024 Dec.30(23):5333-5341. Pubmedid: 39417680. Pmcid: PMC11611651.
• Yao S, Li K, Li T, Yu X, Kuan PF, Wang X. GPS-Net: Discovering prognostic pathway modules based on network regularized kernel learning. Am J Hum Genet. 2024 Dec.111(12):2826-2838. Pubmedid: 39510078. Pmcid: PMC11639089.
• Hänggi K, Li J, Gangadharan A, Liu X, Celias DP, Osunmakinde O, Keske A, Davis J, Ahmad F, Giron A, Anadon CM, Gardner A, DeNardo DG, Shaw TI, Beg AA, Yu X, Ruffell B. Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. Cancer Cell. 2024 Dec.42(12):2015-2031.e11. Pubmedid: 39577420. Pmcid: PMC11631672.
• Diamond B, Chahar D, Jain MD, Poos AM, Durante M, Ziccheddu B, Kaddoura M, Papadimitriou M, Maclachlan K, Jelinek T, Davies F, Figura NB, Morgan G, Mai E, Weisel KC, Fenk R, Raab MS, Usmani S, Landgren O, Locke FL, Goldschmidt H, Schatz JH, Weinhold N, Maura F. Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies. bioRxiv. 2024 Nov. Pubmedid: 39605649. Pmcid: PMC11601314.
• Li T, Patel KB, Yu X, Yao S, Wang L, Chung CH, Wang X. Identifying targeted cell-free DNA methylation regions in head and neck cancer via paired methylome analysis. Res Sq. 2024 Nov. Pubmedid: 39649173. Pmcid: PMC11623779.
• Balagurunathan Y, Wei Z, Qi J, Thompson Z, Dean E, Lu H, Vardhanabhuti S, Corallo S, Choi JW, Kim JJ, Mattie M, Jain M, Locke FL. Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy. Front Oncol. 2024 Nov.14:1485039. Pubmedid: 39659779. Pmcid: PMC11629080.
• Wang T, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Deek MP. Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer. Transl Cancer Res. 2024 Nov.13(11):6235-6245. Pubmedid: 39697761. Pmcid: PMC11651787.
• Luo Y, Chen Y, Ai C, Huang X, Perna F, Kale BJ, Lim SM, Gu M, Gao P, Rong C, Zhou Z, Weng Y, Jiang Y, Yang F, Xia Y. PARP1 promotes tumor proliferation in lenalidomide-resistant multiple myeloma via the downregulation of microRNA-192-5p-AKT signaling. Transl Cancer Res. 2024 Nov.13(11):6273-6281. Pubmedid: 39697751. Pmcid: PMC11651790.
• Alban TJ, Riaz N, Parthasarathy P, Makarov V, Kendall S, Yoo SK, Shah R, Weinhold N, Srivastava R, Ma X, Krishna C, Mok JY, van Esch WJE, Garon E, Akerley W, Creelan B, Aanur N, Chowell D, Geese WJ, Rizvi NA, Chan TA. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Nat Med. 2024 Nov.30(11):3209-3222. Pubmedid: 39349627.
• Goetz JW, Rabinowits G, Kalman N, Villa A. A Review of Immunotherapy for Head and Neck Cancer. J Dent Res. 2024 Nov.103(12):1185-1196. Pubmedid: 39370694. Pmcid: PMC11653306.
• Ozakinci H, Alontaga AY, Cano P, Koomen JM, Perez BA, Beg AA, Chiappori AA, Haura EB, Boyle TA. Unveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel. JTO Clin Res Rep. 2024 Nov.5(11):100723. Pubmedid: 39386315. Pmcid: PMC11459576.
• Keshari S, Shavkunov AS, Miao Q, Saha A, Minowa T, Molgora M, Williams CD, Chaib M, Highsmith AM, Pineda JE, Alekseev S, Alspach E, Hu KH, Colonna M, Pauken KE, Chen K, Gubin MM. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 Nov.43(11):114875. Pubmedid: 39446585.
• Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Marin Falco M, Salvagno C, Emmanuelli A, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Yu X, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR. Transgelin 2 guards T cell lipid metabolism and antitumour function. Nature. 2024 Nov.635(8040):1010-1018. Pubmedid: 39443795.
• Ma Y, Zhao X, Feng J, Qiu S, Ji B, Huang L, Hwu P, Logsdon CD, Wang H. Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer. iScience. 2024 Nov.27(11):111085. Pubmedid: 39473974. Pmcid: PMC11514315.
• Lok V, Olson-McPeek S, Spiegelhoff G, Cortez J, Detz D, Czerniecki B. Immunotherapies in breast cancer: harnessing the cancer immunity cycle. Expert Opin Ther Targets. 2024 Nov.28(11):925-935. Pubmedid: 39523444.
• Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma. Blood Cancer J. 2024 Nov.14(1):197. Pubmedid: 39511146. Pmcid: PMC11544145.
• Karapetyan L, Li A, Vargas De Stefano D, Abushukair HM, Al-Bzour AN, Knight A, Layding C, Wang H, Xu J, Yao J, Song X, Joy M, Nguyen J, Moran-Segura C, Bruno S, Sander C, Messina J, Mule JJ, Storkus WJ, Kirkwood JM. Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024 Nov.12(11). Pubmedid: 39537211. Pmcid: PMC11575263.
• Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, Berkenstock MK, Bermas B, Braaten T, Budde LE, Chokshi S, Crees ZD, Davies M, Deng C, Gesthalter Y, Jain M, Jain P, Jallouk A, Kaffenberger BH, Khalil M, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Prosek J, Reddy S, Reid P, Ryan J, Ryder M, Salman H, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Zucker S, Lyons M, Awotiwon A, Hang L. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. J Natl Compr Canc Ne. 2024 Nov.22(9):582-592. Pubmedid: 39536465.
• Xu YG, Lim Y, Bordeaux JS, Aasi SZ, Alam M, Chen PL, Contreras CM, DiMaio D, Donigan JM, Farma JM, Grekin RC, Mark L, Nehal KS, Nghiem P, Olino K, Patel T, Scott J, Shaha AR, Srivastava D, Schmults CD. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). J Natl Compr Canc Ne. 2024 Nov.22(9). Pubmedid: 39536442.
• Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC, Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood Cancer J. 2024 Nov.14(1):203. Pubmedid: 39562780. Pmcid: PMC11577064.
• Khatri VM, Mestres-Villanueva MA, Yarlagadda S, Doniparthi A, Smith DB, Nakashima JY, Bryant JM, Zhao D, Upadhyay R, Mills MN, Oliver DE, Yu HM, Palmer JD, Williams NO, Mahtani RL, Ahluwalia MS, Soliman HH, Han HS, Soyano AE, Kim Y, Kotecha R, Beyer SJ, Ahmed KA. Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases. NPJ Breast Cancer. 2024 Nov.10(1):100. Pubmedid: 39572568. Pmcid: PMC11582691.
• Wickman E, Lange S, Wagner J, Ibanez J, Tian L, Lu M, Sheppard H, Chiang J, Koo SC, Vogel P, Langfitt D, Perry SS, Shanmugam R, Bell M, Shaw TI, Krenciute G, Zhang J, Gottschalk S. IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors. J Immunother Cancer. 2024 Nov.12(11). Pubmedid: 39572158. Pmcid: PMC11580246.
• J Wu J, Wade SW, Itani T, Castaigne JG, Kloos I, Peng W, Kanters S, Zoratti MJ, Dreyling M, Shah B, Wang M. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis. Leuk Lymphoma. 2024 Nov.65(11):1609-1622. Pubmedid: 38975903.
• Pidala JA, Holtan SG, Walton K, Kim J, Cao B, Elmariah H, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez LE, Faramand RG, Davila ML, McSain S, Pleskow J, Baron J, Anasetti C, Moran Segura CM, Weisdorf DJ, Blazar BR, Miller JS, Bachanova V, El Jurdi N, Betts BC. JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results. Blood. 2024 Nov.144(22):2295-2307. Pubmedid: 39046783. Pmcid: PMC11619790.
• Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, Mishra A, Sweet K, Perez L, Ochoa-Bayona J, Nieder M, Komrokji R, Lancet J, Fernandez H, Nishihori T, Pidala J, Anasetti C, Bejanyan N. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplant Cell Ther. 2024 Nov.30(11):1090.e1-1090.e10. Pubmedid: 39147136.
• Cigliola A, Prakash G, Li R, Oualla K, Gupta S, Kamat AM, Chahoud J, Necchi A, Spiess PE. Correction to: Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions. Curr Oncol Rep. 2024 Nov.26(11):1520. Pubmedid: 39179885.
• Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Kersten MJ, Zheng Y, Zhang T, Nater J, Shen R, Miao H, Kim JJ, Miklos DB. Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Transplant Cell Ther. 2024 Nov.30(11):1065-1079. Pubmedid: 39187161.
• Peters PN, Whitaker RS, Lim F, Russell S, Bloom EA, Pollara J, Strickland KC, Cantwell MJ, Beg A, Berchuck A, Antonia S, Previs RA. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 2024 Nov.57:101056. Pubmedid: 39276533. Pmcid: PMC11417341.